Activation	O
of	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
inflammatory	O
bowel	O
disease	O
[	O
see	O
comments	O
]	O

BACKGROUND	O
:	O
Expression	O
of	O
pro-inflammatory	B-protein
cytokines	I-protein
is	O
increased	O
in	O
the	O
intestinal	O
lamina	O
propria	O
of	O
patients	O
with	O
inflammatory	O
bowel	O
disease	O
(	O
IBD	O
)	O
.	O

Nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
(	O
NF	B-protein
kappa	I-protein
B	I-protein
)	O
controls	O
transcription	O
of	O
inflammation	B-DNA
genes	I-DNA
.	O

On	O
activation	O
,	O
NF	B-protein
kappa	I-protein
B	I-protein
is	O
rapidly	O
released	O
from	O
its	O
cytoplasmic	B-protein
inhibitor	I-protein
(	O
I	B-protein
kappa	I-protein
B	I-protein
)	O
,	O
transmigrates	O
into	O
the	O
nucleus	O
,	O
and	O
binds	O
to	O
DNA	B-DNA
response	I-DNA
elements	I-DNA
in	O
gene	O
promoter	O
regions	O
.	O

AIMS	O
:	O
To	O
investigate	O
whether	O
increased	O
activation	O
of	O
NF	B-protein
kappa	I-protein
B	I-protein
is	O
important	O
in	O
IBD	O
and	O
may	O
be	O
down-regulated	O
by	O
anti-inflammatory	O
treatment	O
.	O

METHODS	O
:	O
Activation	O
of	O
NF	B-protein
kappa	I-protein
B	I-protein
was	O
determined	O
by	O
western	O
blot	O
assessment	O
and	O
electrophoretic	O
mobility	O
shift	O
assay	O
in	O
nuclear	O
extracts	O
of	O
colonic	O
biopsy	O
samples	O
as	O
well	O
as	O
lamina	B-cell_type
propria	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
.	O

RESULTS	O
:	O
Nuclear	O
levels	O
of	O
NF	B-protein
kappa	I-protein
B	I-protein
p65	B-protein
are	O
increased	O
in	O
lamina	O
propria	O
biopsy	O
specimens	O
from	O
patients	O
with	O
Crohn	O
's	O
disease	O
in	O
comparison	O
with	O
patients	O
with	O
ulcerative	O
colitis	O
and	O
controls	O
.	O

Increased	O
activation	O
of	O
NF	B-protein
kappa	I-protein
B	I-protein
was	O
detected	O
in	O
lamina	B-cell_type
propria	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
from	O
patients	O
with	O
active	O
IBD	O
.	O

Corticosteroids	O
strongly	O
inhibit	O
intestinal	O
NF	B-protein
kappa	I-protein
B	I-protein
activation	O
in	O
IBD	O
in	O
vivo	O
and	O
in	O
vitro	O
by	O
stabilising	O
the	O
cytosolic	B-protein
inhibitor	I-protein
I	B-protein
kappa	I-protein
B	I-protein
alpha	O
against	O
activation	O
induced	O
degradation	O
.	O

CONCLUSIONS	O
:	O
In	O
both	O
IBDs	O
,	O
but	O
particularly	O
Crohn	O
's	O
disease	O
,	O
increased	O
activation	O
of	O
NF	B-protein
kappa	I-protein
B	I-protein
may	O
be	O
involved	O
in	O
the	O
regulation	O
of	O
the	O
inflammatory	O
response	O
.	O

Inhibition	O
of	O
NF	B-protein
kappa	I-protein
B	I-protein
activation	O
may	O
represent	O
a	O
mechanism	O
by	O
which	O
steroids	O
exert	O
an	O
anti-inflammatory	O
effect	O
in	O
IBD	O

Gut	NULL
1998	NULL
;	NULL
42:477-484	NULL
Charité	NULL
University	NULL
Hospital	NULL
,	NULL
4th	NULL
Medical	NULL
Department	NULL
,	NULL
Humboldt	NULL
University	NULL
,	NULL
Berlin	NULL
,	NULL
Germany	NULL
S	NULL
Schreiber	NULL
S	NULL
Nikolaus	NULL
]	NULL
Hampe	NULL
Correspondence	NULL
to	NULL
:	NULL
Dr	NULL
Stefan	NULL
Schreiber	NULL
,	NULL
First	NULL
Medical	NULL
Department	NULL
,	NULL
Christian-Albrechts	NULL
University	NULL
,	NULL
Schittenhelmstrasse	NULL
12	NULL
,	NULL
24105	NULL
Kicl	NULL
,	NULL
Germany	NULL
.	NULL

Accepted	NULL
for	NULL
publication	NULL
9	NULL
October	NULL
1997	NULL
477	NULL
Activation	NULL
of	NULL
nuclear	NULL
factor	NULL
xB	NULL
in	NULL
inflammatory	NULL
bowel	NULL
disease	NULL
S	NULL
Schreiber	NULL
,	NULL
S	NULL
Nikolaus	NULL
,	NULL
J	NULL
Hampe	NULL
Abstract	NULL
Background-Expression	NULL
of	NULL
pro-inflammatory	NULL
cytokines	NULL
is	NULL
increased	NULL
in	NULL
the	NULL
intestinal	NULL
lamina	NULL
propria	NULL
of	NULL
patients	NULL
with	NULL
inflammatory	NULL
bowel	NULL
disease	NULL
(	NULL
IBD	NULL
)	NULL
.	NULL

Nuclear	NULL
factor	NULL
xB	NULL
(	NULL
NFB	NULL
)	NULL
controls	NULL
transcription	NULL
of	NULL
inflammation	NULL
genes	NULL
.	NULL

On	NULL
activation	NULL
,	NULL
NFB	NULL
is	NULL
rapidly	NULL
released	NULL
from	NULL
its	NULL
cytoplasmic	NULL
inhibitor	NULL
(	NULL
IxB	NULL
)	NULL
,	NULL
transmigrates	NULL
into	NULL
the	NULL
nucleus	NULL
,	NULL
and	NULL
binds	NULL
to	NULL
DNA	NULL
response	NULL
elements	NULL
in	NULL
gene	NULL
promoter	NULL
re-gions	NULL
.	NULL

Aims-To	NULL
investigate	NULL
whether	NULL
increased	NULL
activation	NULL
of	NULL
NFxB	NULL
is	NULL
important	NULL
in	NULL
IBD	NULL
and	NULL
may	NULL
be	NULL
down-regulated	NULL
by	NULL
anti-inflammatory	NULL
treatment	NULL
.	NULL

Methods-Activation	NULL
of	NULL
NFxB	NULL
was	NULL
determined	NULL
by	NULL
western	NULL
blot	NULL
assessment	NULL
and	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
assay	NULL
in	NULL
nuclear	NULL
extracts	NULL
of	NULL
colonic	NULL
biopsy	NULL
samples	NULL
as	NULL
well	NULL
as	NULL
lamina	NULL
propria	NULL
mononuclear	NULL
cells	NULL
.	NULL

Results-Nuclear	NULL
levels	NULL
of	NULL
NFB	NULL
p65	NULL
are	NULL
increased	NULL
in	NULL
lamina	NULL
propria	NULL
biopsy	NULL
specimens	NULL
from	NULL
patients	NULL
with	NULL
Crohn	NULL
's	NULL
disease	NULL
in	NULL
comparison	NULL
with	NULL
patients	NULL
with	NULL
ulcerative	NULL
colitis	NULL
and	NULL
controls	NULL
.	NULL

Increased	NULL
activation	NULL
of	NULL
NFB	NULL
was	NULL
detected	NULL
in	NULL
lamina	NULL
propria	NULL
mononuclear	NULL
cells	NULL
from	NULL
patients	NULL
with	NULL
active	NULL
IBD	NULL
.	NULL

Corticosteroids	NULL
strongly	NULL
inhibit	NULL
intestinal	NULL
NFxB	NULL
activation	NULL
in	NULL
IBD	NULL
in	NULL
vivo	NULL
and	NULL
in	NULL
vitro	NULL
by	NULL
stabilising	NULL
the	NULL
cytosolic	NULL
inhibitor	NULL
IxBa	NULL
against	NULL
activation	NULL
induced	NULL
degradation	NULL
.	NULL

Conclusions-In	NULL
both	NULL
IBDs	NULL
,	NULL
but	NULL
particularly	NULL
Crohn	NULL
's	NULL
disease	NULL
,	NULL
increased	NULL
activation	NULL
of	NULL
NFxB	NULL
may	NULL
be	NULL
involved	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
the	NULL
inflammatory	NULL
response	NULL
.	NULL

Inhibition	NULL
of	NULL
NFkB	NULL
activation	NULL
may	NULL
represent	NULL
a	NULL
mechanism	NULL
by	NULL
which	NULL
steroids	NULL
exert	NULL
an	NULL
anti-inflammatory	NULL
effect	NULL
in	NULL
IBD	NULL
.	NULL

(	NULL
Gut	NULL
1998	NULL
;	NULL
42:477-484	NULL
)	NULL
Keywords	NULL
:	NULL
interleukin	NULL
18	NULL
;	NULL
inflammatory	NULL
bowel	NULL
disease	NULL
;	NULL
intestinal	NULL
immunity	NULL
;	NULL
signal	NULL
transduction	NULL
;	NULL
steroids	NULL
;	NULL
tumour	NULL
necrosis	NULL
factor	NULL
a	NULL
Recent	NULL
studies	NULL
have	NULL
shown	NULL
increased	NULL
production	NULL
of	NULL
pro-inflammatory	NULL
cytokines	NULL
including	NULL
interleukin	NULL
(	NULL
IL	NULL
)	NULL
18	NULL
and	NULL
tumour	NULL
necrosis	NULL
factor	NULL
a	NULL
(	NULL
INF-aq	NULL
)	NULL
in	NULL
inflammatory	NULL
bowel	NULL
disease	NULL
(	NULL
IBD	NULL
)	NULL
.	NULL

Increased	NULL
levels	NULL
of	NULL
TNF-a	NULL
have	NULL
also	NULL
been	NULL
reported	NULL
in	NULL
stools	NULL
of	NULL
children	NULL
with	NULL
active	NULL
Crohn	NULL
's	NULL
disease	NULL
.	NULL
``	NULL

The	NULL
increased	NULL
production	NULL
of	NULL
pro-inflammatory	NULL
cytokines	NULL
in	NULL
the	NULL
intestinal	NULL
mucosa	NULL
is	NULL
thought	NULL
to	NULL
be	NULL
an	NULL
important	NULL
factor	NULL
in	NULL
the	NULL
pathophysiology	NULL
of	NULL
intestinal	NULL
inflammation	NULL
in	NULL
IBD	NULL
.	NULL

**	NULL
However	NULL
,	NULL
the	NULL
pivotal	NULL
elements	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
the	NULL
increased	NULL
inflammatory	NULL
activity	NULL
remain	NULL
unclear	NULL
.	NULL

Important	NULL
candidates	NULL
are	NULL
transcription	NULL
factors	NULL
that	NULL
bind	NULL
to	NULL
gene	NULL
promoter	NULL
regions	NULL
and	NULL
are	NULL
involved	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
inflammation	NULL
gene	NULL
transcription	NULL
.	NULL

Nuclear	NULL
factor	NULL
xB	NULL
(	NULL
NFxB	NULL
)	NULL
was	NULL
originally	NULL
defined	NULL
as	NULL
a	NULL
heterodimeric	NULL
complex	NULL
of	NULL
two	NULL
subunits	NULL
,	NULL
p65	NULL
and	NULL
p50.°	NULL
°	NULL
The	NULL
NFxB	NULL
family	NULL
includes	NULL
the	NULL
proteins	NULL
p50	NULL
and	NULL
its	NULL
precursor	NULL
p105	NULL
(	NULL
NFxB1	NULL
)	NULL
,	NULL
p52	NULL
and	NULL
its	NULL
precursor	NULL
p100	NULL
(	NULL
NFxB2	NULL
)	NULL
,	NULL
p65	NULL
(	NULL
RelA	NULL
)	NULL
,	NULL
c-Rel	NULL
,	NULL
and	NULL
Rel	NULL
B	NULL
.	NULL
``	NULL

°	NULL
Functionally	NULL
active	NULL
NFxB	NULL
represents	NULL
homo-	NULL
or	NULL
hetero-dimers	NULL
of	NULL
members	NULL
of	NULL
the	NULL
Rel	NULL
family	NULL
of	NULL
transcription	NULL
factor	NULL
proteins	NULL
,	NULL
which	NULL
mostly	NULL
include	NULL
p65	NULL
as	NULL
one	NULL
of	NULL
the	NULL
molecules	NULL
.	NULL

The	NULL
main	NULL
function	NULL
of	NULL
NFxB	NULL
appears	NULL
to	NULL
be	NULL
the	NULL
transcriptional	NULL
regulation	NULL
of	NULL
certain	NULL
genes	NULL
as	NULL
a	NULL
transactivating	NULL
factor	NULL
.	NULL

Binding	NULL
of	NULL
NFxB	NULL
to	NULL
specific	NULL
DNA	NULL
sequences	NULL
located	NULL
in	NULL
gene	NULL
promoter	NULL
regions	NULL
is	NULL
a	NULL
pivotal	NULL
event	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
transcriptional	NULL
events	NULL
by	NULL
the	NULL
factor	NULL
.	NULL
``	NULL

°	NULL
NFrB	NULL
was	NULL
originally	NULL
defined	NULL
by	NULL
its	NULL
ability	NULL
to	NULL
bind	NULL
to	NULL
a	NULL
10	NULL
bp	NULL
oligonucleotide	NULL
motif	NULL
first	NULL
identified	NULL
in	NULL
the	NULL
enhancer	NULL
region	NULL
of	NULL
the	NULL
immunoglobulin	NULL
x	NULL
light	NULL
chain	NULL
gene	NULL
.	NULL

Using	NULL
labelled	NULL
oligonucleotides	NULL
resembling	NULL
this	NULL
binding	NULL
sequence	NULL
,	NULL
NFxB	NULL
can	NULL
be	NULL
assessed	NULL
semmiquantitatively	NULL
by	NULL
the	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
assay	NULL
(	NULL
EMSA	NULL
)	NULL
.	NULL
``	NULL

The	NULL
detection	NULL
of	NULL
specific	NULL
DNA	NULL
binding	NULL
describes	NULL
a	NULL
crucial	NULL
event	NULL
in	NULL
the	NULL
mechanisms	NULL
of	NULL
transcriptional	NULL
regulation	NULL
by	NULL
NFxB	NULL
,	NULL
although	NULL
further	NULL
steps	NULL
are	NULL
necessary	NULL
for	NULL
the	NULL
factor	NULL
to	NULL
exert	NULL
control	NULL
over	NULL
inflammation	NULL
gene	NULL
transcription	NULL
.	NULL

Most	NULL
proteins	NULL
of	NULL
the	NULL
NFxB	NULL
family	NULL
are	NULL
consti-tutively	NULL
present	NULL
in	NULL
the	NULL
cytoplasm	NULL
of	NULL
mononuclear	NULL
phagocytes	NULL
.	NULL

In	NULL
resting	NULL
cells	NULL
,	NULL
they	NULL
are	NULL
bound	NULL
to	NULL
inactivating	NULL
molecules	NULL
such	NULL
as	NULL
inhibitor	NULL
xB	NULL
a	NULL
(	NULL
IxBa	NULL
)	NULL
or	NULL
large	NULL
NFxB	NULL
precursors-for	NULL
example	NULL
,	NULL
p105	NULL
.	NULL

``	NULL
°	NULL
A	NULL
host	NULL
of	NULL
activating	NULL
stimuli	NULL
including	NULL
lipopolysaccharide	NULL
(	NULL
LPS	NULL
)	NULL
and	NULL
TNF-a	NULL
induce	NULL
site	NULL
specific	NULL
phosphorylation	NULL
of	NULL
IxBa	NULL
and	NULL
consecutive	NULL
rapid	NULL
dissociation	NULL
of	NULL
the	NULL
complex	NULL
accompanied	NULL
by	NULL
proteolytic	NULL
degradation	NULL
of	NULL
IxBa	NULL
.	NULL
``	NULL

''	NULL
The	NULL
released	NULL
NFxB	NULL
proteins	NULL
subsequently	NULL
transmigrate	NULL
from	NULL
the	NULL
cytoplasm	NULL
into	NULL
the	NULL
nucleus	NULL
where	NULL
they	NULL
can	NULL
augment	NULL
transcription	NULL
of	NULL
specific	NULL
genes	NULL
in	NULL
synergy	NULL
with	NULL
other	NULL
pro-inflammatory	NULL
transcription	NULL
factors	NULL
including	NULL
NF-IL6	NULL
.	NULL

*	NULL
``	NULL
Nuclear	NULL
translocation	NULL
of	NULL
both	NULL
NFxB	NULL
p50	NULL
and	NULL
p65	NULL
can	NULL
be	NULL
blocked	NULL
by	NULL
the	NULL
serine	NULL
protease	NULL
inhibitor	NULL
N-a-tosyl-phenylalanine	NULL
chloromethyl	NULL
ketone	NULL
(	NULL
TPCK	NULL
)	NULL
,	NULL
which	NULL
stabilises	NULL
IxBa	NULL
against	NULL
degradation	NULL
.	NULL
``	NULL

NFxrB	NULL
may	NULL
play	NULL
a	NULL
central	NULL
role	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
chronic	NULL
inflammation	NULL
by	NULL
controlling	NULL
the	NULL
transcription	NULL
of	NULL
inflammation	NULL
genes	NULL
.	NULL

Many	NULL
of	NULL
the	NULL
pro-inflammatory	NULL
cytokine	NULL
genes	NULL
include	NULL
NFxB	NULL
binding	NULL
sites	NULL
,	NULL
and	NULL
most	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
be	NULL
transcriptionally	NULL
regulated	NULL
by	NULL
the	NULL
factor	NULL
.	NULL
``	NULL

°	NULL
``	NULL
'*	NULL
478	NULL
Table	NULL
1	NULL
-	NULL
Clinical	NULL
characteristics	NULL
of	NULL
patients	NULL
used	NULL
in	NULL
figures	NULL
1	NULL
and	NULL
2	NULL
Schreiber	NULL
,	NULL
Nikolaus	NULL
,	NULL
Hampe	NULL
Duration	NULL
of	NULL
Sex	NULL
-	NULL
Age	NULL
disease	NULL
CDAI	NULL
Endoscopic	NULL
vity	NULL
-	NULL
Biopsy	NULL
l	NULL
Mesalazi	NULL
Invol	NULL
ileallileocolonic/colonic/left-sided	NULL
)	NULL
No	NULL
Diagnosis	NULL
-	NULL
MIF	NULL
-	NULL
(	NULL
years	NULL
)	NULL
-	NULL
(	NULL
year	NULL
)	NULL
*	NULL
CAI	NULL
n/mimd/st	NULL
clahtldlsir	NULL
}	NULL
treatment	NULL
yes/no	NULL
_	NULL
diagnosis	NULL
(	NULL
DSC	NULL
only	NULL
)	NULL
1-10	NULL
CD	NULL
4/6	NULL
19-54	NULL
1-17	NULL
187-412	NULL
0/24/74	NULL
5/1/0/3/1/0	NULL
7/3	NULL
O/8/2/NA	NULL
11-24	NULL
UC	NULL
6/8	NULL
17-51	NULL
.	NULL

1-28	NULL
6-12	NULL
0/2/8/4	NULL
10/0/0/3/1/0	NULL
12/2	NULL
NA/3/T/A	NULL
25	NULL
DSC	NULL
F	NULL
26	NULL
2	NULL
weeks	NULL
NA	NULL
md	NULL
s	NULL
No	NULL
Salmonellosis	NULL
26	NULL
DSC	NULL
M	NULL
31	NULL
3	NULL
days	NULL
NA	NULL
md	NULL
s	NULL
No	NULL
Yersiniosis	NULL
27	NULL
DSC	NULL
F	NULL
27	NULL
2	NULL
days	NULL
NA	NULL
s	NULL
s	NULL
No	NULL
Unclear	NULL
inflammation	NULL
adjacent	NULL
to	NULL
colonic	NULL
carcinoma	NULL
28	NULL
DSC	NULL
F	NULL
55	NULL
3	NULL
NA	NULL
md	NULL
d	NULL
No	NULL
Diverticulitis	NULL
29	NULL
DSC	NULL
F	NULL
61	NULL
7	NULL
NA	NULL
md	NULL
d	NULL
No	NULL
Diverticulitis	NULL
30	NULL
DSC	NULL
M	NULL
27	NULL
4	NULL
days	NULL
NA	NULL
md	NULL
s	NULL
No	NULL
Viral	NULL
enterocolitis	NULL
*Range	NULL
(	NULL
minimum-maximum	NULL
)	NULL
.	NULL

{	NULL
n	NULL
,	NULL
none	NULL
;	NULL
m	NULL
,	NULL
mild	NULL
;	NULL
md	NULL
,	NULL
moderate	NULL
;	NULL
s	NULL
,	NULL
severe	NULL
,	NULL
according	NULL
to	NULL
endoscopist	NULL
's	NULL
assessment	NULL
of	NULL
the	NULL
biopsy	NULL
site	NULL
.	NULL

fc	NULL
,	NULL
caecum	NULL
;	NULL
a	NULL
,	NULL
ascending	NULL
colon	NULL
;	NULL
t	NULL
,	NULL
transverse	NULL
colon	NULL
;	NULL
d	NULL
,	NULL
descending	NULL
colon	NULL
;	NULL
s	NULL
,	NULL
sigmoid	NULL
;	NULL
r	NULL
,	NULL
rectum	NULL
.	NULL

Biopsy	NULL
samples	NULL
were	NULL
always	NULL
taken	NULL
from	NULL
the	NULL
area	NULL
showing	NULL
the	NULL
highest	NULL
degree	NULL
of	NULL
inflammatory	NULL
activity	NULL
.	NULL

Necrotic	NULL
areas	NULL
were	NULL
not	NULL
sampled	NULL
.	NULL

NA	NULL
,	NULL
not	NULL
applicable	NULL
;	NULL
CD	NULL
,	NULL
Crohn	NULL
's	NULL
disease	NULL
;	NULL
UC	NULL
,	NULL
ulcerative	NULL
colitis	NULL
;	NULL
DSC	NULL
,	NULL
disease	NULL
specificity	NULL
control	NULL
;	NULL
CDAI	NULL
,	NULL
Crohn	NULL
's	NULL
disease	NULL
activity	NULL
index	NULL
``	NULL
``	NULL
;	NULL
CAL	NULL
,	NULL
colitis	NULL
activity	NULL
index	NULL
.	NULL
``	NULL

(	NULL
lic	NULL
mmm	NULL
oom	NULL
oms	NULL
.	NULL

mms	NULL
mae	NULL
mate	NULL
n	NULL
w	NULL
Most	NULL
interestingly	NULL
,	NULL
NFxB	NULL
dimers	NULL
containing	NULL
p65	NULL
appear	NULL
to	NULL
have	NULL
profound	NULL
pro-inflammatory	NULL
activity	NULL
,	NULL
whereas	NULL
the	NULL
p50	NULL
hom-odimer	NULL
(	NULL
NFxB1	NULL
)	NULL
is	NULL
either	NULL
inactive	NULL
or	NULL
may	NULL
even	NULL
be	NULL
involved	NULL
in	NULL
blocking	NULL
NFxB	NULL
sites	NULL
in	NULL
some	NULL
inflammation	NULL
gene	NULL
promoters	NULL
against	NULL
binding	NULL
of	NULL
p65	NULL
dimers	NULL
.	NULL
'	NULL

''	NULL
``	NULL
``	NULL
Overexpression	NULL
of	NULL
p50	NULL
homodimers	NULL
has	NULL
been	NULL
suggested	NULL
to	NULL
be	NULL
the	NULL
mechanism	NULL
of	NULL
LPS	NULL
refractoriness	NULL
following	NULL
repetitive	NULL
stimulation	NULL
-	NULL
of	NULL
-	NULL
mononuclear	NULL
phagocytes	NULL
.	NULL
``	NULL

Recent	NULL
studies	NULL
suggest	NULL
that	NULL
activation	NULL
of	NULL
NFxB	NULL
involving	NULL
the	NULL
p65	NULL
subunit	NULL
may	NULL
be	NULL
a	NULL
key	NULL
event	NULL
in	NULL
trinitrobenzenesulphonic	NULL
acid	NULL
(	NULL
TNBS	NULL
)	NULL
/ethanol	NULL
colitis	NULL
.	NULL
``	NULL

Although	NULL
not	NULL
shown	NULL
in	NULL
vivo	NULL
,	NULL
a	NULL
role	NULL
for	NULL
NFxB	NULL
p65	NULL
activation	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
intestinal	NULL
inflammation	NULL
in	NULL
IBD	NULL
seems	NULL
likely	NULL
.	NULL

In	NULL
this	NULL
study	NULL
we	NULL
show	NULL
increased	NULL
levels	NULL
of	NULL
NFxB	NULL
p65	NULL
in	NULL
nuclear	NULL
extracts	NULL
of	NULL
intestinal	NULL
lamina	NULL
propria	NULL
biopsy	NULL
samples	NULL
from	NULL
patients	NULL
with	NULL
IBD	NULL
.	NULL

Nuclear	NULL
extracts	NULL
from	NULL
lamina	NULL
propria	NULL
of	NULL
patients	NULL
with	NULL
Crohn	NULL
's	NULL
disease	NULL
,	NULL
a	NULL
disease	NULL
in	NULL
which	NULL
a	NULL
particular	NULL
role	NULL
for	NULL
TNF-a	NULL
has	NULL
been	NULL
suggested	NULL
,	NULL
``	NULL
'	NULL
contained	NULL
substantially	NULL
higher	NULL
levels	NULL
of	NULL
NFxB	NULL
p65	NULL
C	NULL
U	NULL
CC	NULL
PRNMUY	NULL
D	NULL
C	NULL
UV	NULL
U	NULL
bo	NULL
NCN	NULL
U	NULL
U	NULL
C	NULL
an	NULL
i	NULL
lige	NULL
on	NULL
tm	NULL
mom	NULL
Figure	NULL
1	NULL
-	NULL
NFKB	NULL
p65	NULL
in	NULL
nuclear	NULL
extracts	NULL
from	NULL
colonic	NULL
biospsy	NULL
samples	NULL
.	NULL

Colonic	NULL
biopsy	NULL
specimens	NULL
from	NULL
10	NULL
patients	NULL
with	NULL
active	NULL
Crohn	NULL
's	NULL
disease	NULL
(	NULL
CD	NULL
)	NULL
,	NULL
14	NULL
patients	NULL
with	NULL
active	NULL
ulcerative	NULL
colitis	NULL
(	NULL
UC	NULL
)	NULL
,	NULL
six	NULL
disease	NULL
specificity	NULL
controls	NULL
(	NULL
DSC	NULL
)	NULL
,	NULL
and	NULL
seven	NULL
normal	NULL
controls	NULL
(	NULL
NC	NULL
)	NULL
were	NULL
extracted	NULL
using	NULL
a	NULL
procedure	NULL
to	NULL
isolate	NULL
the	NULL
nuclear	NULL
compartment	NULL
.	NULL

Densitometric	NULL
readings	NULL
from	NULL
western	NULL
blot	NULL
assessments	NULL
of	NULL
NFKB	NULL
p65	NULL
are	NULL
demonstrated	NULL
by	NULL
the	NULL
bar	NULL
graph	NULL
(	NULL
mean	NULL
(	NULL
SD	NULL
)	NULL
)	NULL
.	NULL

Before	NULL
electrophoresis	NULL
,	NULL
samples	NULL
were	NULL
adjusted	NULL
to	NULL
have	NULL
equal	NULL
contents	NULL
of	NULL
total	NULL
protein	NULL
.	NULL

The	NULL
inset	NULL
shows	NULL
a	NULL
representative	NULL
sample	NULL
of	NULL
the	NULL
original	NULL
blots	NULL
.	NULL

Individuals	NULL
are	NULL
marked	NULL
on	NULL
the	NULL
blot	NULL
with	NULL
U	NULL
(	NULL
ulcerative	NULL
colitis	NULL
)	NULL
,	NULL
C	NULL
(	NULL
Crohn	NULL
's	NULL
disease	NULL
)	NULL
,	NULL
D	NULL
(	NULL
disease	NULL
specificity	NULL
controls	NULL
)	NULL
,	NULL
or	NULL
N	NULL
(	NULL
normal	NULL
volunteer	NULL
)	NULL
.	NULL

The	NULL
characteristics	NULL
of	NULL
the	NULL
patients	NULL
and	NULL
localisation	NULL
of	NULL
the	NULL
biopsy	NULL
samples	NULL
are	NULL
shown	NULL
in	NULL
table	NULL
1	NULL
.	NULL

The	NULL
disease	NULL
specificity	NULL
control	NULL
patients	NULL
shown	NULL
in	NULL
the	NULL
blot	NULL
are	NULL
patients	NULL
28	NULL
,	NULL
25	NULL
,	NULL
27	NULL
,	NULL
and	NULL
29	NULL
(	NULL
from	NULL
left	NULL
to	NULL
right	NULL
)	NULL
.	NULL

than	NULL
those	NULL
from	NULL
patients	NULL
with	NULL
ulcerative	NULL
colitis	NULL
.	NULL

Total	NULL
mucosal	NULL
levels	NULL
of	NULL
IxBa	NULL
«	NULL
are	NULL
not	NULL
different	NULL
in	NULL
patients	NULL
with	NULL
IBD	NULL
and	NULL
controls	NULL
.	NULL

Biopsy	NULL
specimens	NULL
as	NULL
well	NULL
as	NULL
isolated	NULL
lamina	NULL
propria	NULL
mononuclear	NULL
cells	NULL
(	NULL
LPMNCs	NULL
)	NULL
from	NULL
patients	NULL
with	NULL
active	NULL
IBD	NULL
show	NULL
enhanced	NULL
activation	NULL
of	NULL
NFxB	NULL
in	NULL
comparison	NULL
with	NULL
controls	NULL
.	NULL

Therefore	NULL
activation	NULL
of	NULL
NFxB	NULL
,	NULL
which	NULL
involves	NULL
the	NULL
p65	NULL
subunit	NULL
,	NULL
may	NULL
contribute	NULL
to	NULL
the	NULL
enhanced	NULL
expression	NULL
of	NULL
inflammation	NULL
genes	NULL
observed	NULL
in	NULL
IBD	NULL
.	NULL

Steroids	NULL
protect	NULL
IxBa	NULL
from	NULL
degradation	NULL
in	NULL
vitro	NULL
and	NULL
thereby	NULL
reduce	NULL
the	NULL
amount	NULL
of	NULL
available	NULL
functionally	NULL
active	NULL
nuclear	NULL
NFxB	NULL
by	NULL
inhibiting	NULL
translocation	NULL
of	NULL
the	NULL
p65	NULL
subunit	NULL
.	NULL

Inhibition	NULL
of	NULL
NFxB	NULL
driven	NULL
transcriptional	NULL
control	NULL
of	NULL
pro-inflammatory	NULL
cytokines	NULL
may	NULL
be	NULL
an	NULL
important	NULL
factor	NULL
in	NULL
the	NULL
anti-inflammatory	NULL
action	NULL
of	NULL
steroids	NULL
in	NULL
IBD	NULL
.	NULL

Materials	NULL
and	NULL
methods	NULL
Fetal	NULL
calf	NULL
serum	NULL
was	NULL
purchased	NULL
from	NULL
Gibco	NULL
(	NULL
Grand	NULL
Island	NULL
,	NULL
NY	NULL
,	NULL
USA	NULL
)	NULL
or	NULL
Sigma	NULL
(	NULL
St	NULL
Louis	NULL
,	NULL
MO	NULL
,	NULL
USA	NULL
)	NULL
.	NULL

Cytokine	NULL
enzyme	NULL
linked	NULL
immuno-sorbent	NULL
assay	NULL
(	NULL
ELISA	NULL
)	NULL
kits	NULL
were	NULL
obtained	NULL
from	NULL
Genzyme/Virotech	NULL
(	NULL
Riisselsheim	NULL
,	NULL
Germany	NULL
)	NULL
and	NULL
from	NULL
DPC	NULL
Biermann	NULL
(	NULL
Bad	NULL
Nauheim	NULL
,	NULL
Germany	NULL
)	NULL
.	NULL

Recombinant	NULL
TNF-u	NULL
was	NULL
purchased	NULL
from	NULL
Genzyme	NULL
,	NULL
and	NULL
antibodies	NULL
against	NULL
IxBa	NULL
and	NULL
NFxB	NULL
p65	NULL
from	NULL
Santa	NULL
Cruz	NULL
(	NULL
Heidelberg	NULL
,	NULL
Germany	NULL
)	NULL
.	NULL

All	NULL
other	NULL
chemicals	NULL
were	NULL
obtained	NULL
from	NULL
Sigma	NULL
if	NULL
not	NULL
specified	NULL
differently	NULL
.	NULL

TPCK	NULL
was	NULL
obtained	NULL
from	NULL
Calbiochem/Nitric	NULL
Oxide	NULL
Research	NULL
(	NULL
La	NULL
Jolla	NULL
,	NULL
CA	NULL
,	NULL
USA	NULL
)	NULL
.	NULL

PATIENTS	NULL
A	NULL
total	NULL
of	NULL
35	NULL
patients	NULL
with	NULL
active	NULL
Crohn	NULL
's	NULL
disease	NULL
and	NULL
39	NULL
patients	NULL
with	NULL
active	NULL
ulcerative	NULL
colitis	NULL
participated	NULL
in	NULL
the	NULL
study	NULL
(	NULL
the	NULL
exact	NULL
numbers	NULL
of	NULL
patients	NULL
being	NULL
investigated	NULL
in	NULL
the	NULL
different	NULL
experiments	NULL
conducted	NULL
are	NULL
indi-cated	NULL
)	NULL
.	NULL

All	NULL
patients	NULL
with	NULL
IBD	NULL
were	NULL
attending	NULL
the	NULL
outpatient	NULL
clinics	NULL
of	NULL
the	NULL
Charité	NULL
University	NULL
Hospital	NULL
in	NULL
Berlin	NULL
because	NULL
of	NULL
increased	NULL
clinical	NULL
activity	NULL
.	NULL

At	NULL
the	NULL
time	NULL
that	NULL
blood	NULL
was	NULL
withdrawn	NULL
or	NULL
mucosal	NULL
biopsy	NULL
samples	NULL
were	NULL
obtained	NULL
,	NULL
25/35	NULL
patients	NULL
with	NULL
Crohn	NULL
's	NULL
disease	NULL
and	NULL
35/39	NULL
patients	NULL
with	NULL
ulcerative	NULL
colitis	NULL
were	NULL
receiving	NULL
treatment	NULL
with	NULL
oral	NULL
salicylates	NULL
(	NULL
mesalazine	NULL
(	NULL
Salofalk	NULL
,	NULL
Claversal	NULL
or	NULL
Pentasa	NULL
)	NULL
,	NULL
salazosulfapy-ridine	NULL
(	NULL
Azulfidine	NULL
or	NULL
Colopleon	NULL
)	NULL
,	NULL
olsalazine	NULL
(	NULL
Dipentum	NULL
)	NULL
)	NULL
.	NULL

None	NULL
of	NULL
the	NULL
patients	NULL
were	NULL
being	NULL
treated	NULL
with	NULL
steroids	NULL
or	NULL
cytotoxic	NULL
drugs	NULL
,	NULL
immu-nosuppressives	NULL
or	NULL
antibiotics	NULL
.	NULL

All	NULL
patients	NULL
NFB	NULL
in	NULL
inflammatory	NULL
bowel	NULL
disease	NULL
cog	NULL
woW	NULL
MOW	NULL
ND	NULL
0	NULL
o	NULL
isd	NULL
mms	NULL
am	NULL
ar	NULL
an	NULL
r	NULL
on	NULL
cm	NULL
1	NULL
)	NULL
ur	NULL
OD	NULL
x	NULL
&	NULL
NFzB	NULL
p55	NULL
foptionl	NULL
density	NULL
ob	NULL
q	NULL
'	NULL
LAs	NULL
L	NULL
LHSI	NULL
NC	NULL
Figure	NULL
2	NULL
-	NULL
Total	NULL
NFKB	NULL
p65	NULL
and	NULL
IxBa	NULL
in	NULL
colonic	NULL
biospy	NULL
tissue	NULL
.	NULL

Colonic	NULL
biopsy	NULL
specimens	NULL
were	NULL
homogenised	NULL
and	NULL
analysed	NULL
by	NULL
western	NULL
blot	NULL
without	NULL
prior	NULL
compartmentalised	NULL
extraction	NULL
.	NULL

Densitometric	NULL
readings	NULL
are	NULL
shown	NULL
by	NULL
the	NULL
bar	NULL
graph	NULL
(	NULL
mean	NULL
(	NULL
SD	NULL
)	NULL
)	NULL
.	NULL

The	NULL
filled	NULL
bars	NULL
show	NULL
levels	NULL
of	NULL
total	NULL
NFKB	NULL
p65	NULL
(	NULL
left	NULL
y	NULL
axis	NULL
)	NULL
,	NULL
and	NULL
the	NULL
shaded	NULL
bars	NULL
levels	NULL
of	NULL
IxBa	NULL
(	NULL
right	NULL
y	NULL
axis	NULL
)	NULL
.	NULL

Before	NULL
electrophoresis	NULL
,	NULL
samples	NULL
were	NULL
adjusted	NULL
to	NULL
have	NULL
equal	NULL
contents	NULL
of	NULL
total	NULL
protein	NULL
.	NULL

No	NULL
statistical	NULL
differences	NULL
were	NULL
seen	NULL
between	NULL
patients	NULL
with	NULL
active	NULL
Crohn	NULL
's	NULL
disease	NULL
(	NULL
CD	NULL
,	NULL
n	NULL
=	NULL
6	NULL
)	NULL
,	NULL
patients	NULL
with	NULL
active	NULL
ulcerative	NULL
colitis	NULL
(	NULL
UC	NULL
,	NULL
n	NULL
=	NULL
6	NULL
)	NULL
,	NULL
disease	NULL
specificity	NULL
controls	NULL
(	NULL
DSC	NULL
,	NULL
n	NULL
=	NULL
6	NULL
)	NULL
,	NULL
and	NULL
normal	NULL
controls	NULL
(	NULL
NGC	NULL
,	NULL
n	NULL
=	NULL
5	NULL
)	NULL
.	NULL

The	NULL
inset	NULL
shows	NULL
representative	NULL
blots	NULL
(	NULL
C	NULL
=	NULL
Crohn	NULL
's	NULL
disease	NULL
,	NULL
U	NULL
=	NULL
ulcerative	NULL
colitis	NULL
,	NULL
D	NULL
=	NULL
disease	NULL
specificity	NULL
control	NULL
,	NULL
and	NULL
N	NULL
=	NULL
normal	NULL
control	NULL
)	NULL
.	NULL

Biopsy	NULL
specimens	NULL
were	NULL
taken	NULL
from	NULL
the	NULL
same	NULL
location	NULL
as	NULL
those	NULL
used	NULL
for	NULL
nuclear	NULL
extracts	NULL
(	NULL
fig	NULL
1	NULL
)	NULL
.	NULL

underwent	NULL
sigmoidoscopy	NULL
or	NULL
colonoscopy	NULL
for	NULL
routine	NULL
clinical	NULL
evaluation	NULL
.	NULL

Only	NULL
patients	NULL
with	NULL
inflammatory	NULL
activity	NULL
indicated	NULL
by	NULL
endoscopic	NULL
assessment	NULL
were	NULL
included	NULL
.	NULL

Infection	NULL
or	NULL
parasites	NULL
were	NULL
excluded	NULL
by	NULL
stool	NULL
cultures	NULL
,	NULL
microscopic	NULL
stool	NULL
examination	NULL
,	NULL
and	NULL
serology	NULL
(	NULL
yers-inia	NULL
)	NULL
.	NULL

Blood	NULL
was	NULL
withdrawn	NULL
after	NULL
informed	NULL
consent	NULL
,	NULL
and	NULL
the	NULL
study	NULL
was	NULL
granted	NULL
prior	NULL
approval	NULL
by	NULL
the	NULL
institutional	NULL
review	NULL
board	NULL
.	NULL

Normal	NULL
controls	NULL
were	NULL
age	NULL
and	NULL
sex	NULL
matched	NULL
healthy	NULL
volunteers	NULL
.	NULL

Disease	NULL
specificity	NULL
controls	NULL
included	NULL
patients	NULL
with	NULL
diverticulitis	NULL
,	NULL
salmonel-losis	NULL
,	NULL
and	NULL
infectious	NULL
enterocolitis	NULL
.	NULL

HUMAN	NULL
LPMNCsS	NULL
Colonic	NULL
biopsy	NULL
specimens	NULL
were	NULL
obtained	NULL
during	NULL
routine	NULL
colonoscopy	NULL
,	NULL
and	NULL
LPMNCs	NULL
were	NULL
isolated	NULL
from	NULL
intestinal	NULL
mucosa	NULL
biopsy	NULL
samples	NULL
as	NULL
described	NULL
previously	NULL
.	NULL
``	NULL

In	NULL
brief	NULL
,	NULL
after	NULL
overnight	NULL
collagenase	NULL
digestion	NULL
,	NULL
the	NULL
cell	NULL
suspension	NULL
was	NULL
collected	NULL
,	NULL
layered	NULL
on	NULL
a	NULL
Ficoll-Hypaque	NULL
gradient	NULL
(	NULL
specific	NULL
gravity	NULL
1.077	NULL
)	NULL
,	NULL
and	NULL
centrifuged	NULL
at	NULL
400	NULL
g	NULL
for	NULL
40	NULL
minutes	NULL
.	NULL

Cells	NULL
were	NULL
harvested	NULL
from	NULL
the	NULL
interphase	NULL
between	NULL
medium	NULL
and	NULL
Ficoll	NULL
,	NULL
washed	NULL
and	NULL
resuspended	NULL
in	NULL
10	NULL
ml	NULL
phosphate	NULL
buffered	NULL
saline	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
neonatal	NULL
calf	NULL
serum	NULL
,	NULL
centrifuged	NULL
at	NULL
500	NULL
g	NULL
for	NULL
15	NULL
minutes	NULL
,	NULL
and	NULL
the	NULL
cell	NULL
pellet	NULL
resuspended	NULL
in	NULL
culture	NULL
medium	NULL
.	NULL

The	NULL
percentage	NULL
of	NULL
macro-phages	NULL
was	NULL
determined	NULL
by	NULL
both	NULL
non-specific	NULL
esterase	NULL
detection	NULL
(	NULL
Sigma	NULL
)	NULL
and	NULL
staining	NULL
for	NULL
CD68	NULL
(	NULL
Dako	NULL
Diagnostika	NULL
GmbH	NULL
,	NULL
Hamburg	NULL
,	NULL
Germany	NULL
)	NULL
using	NULL
the	NULL
alkaline	NULL
phosphatase-anti-alkaline	NULL
phosphatase	NULL
(	NULL
APAAP	NULL
)	NULL
technique	NULL
(	NULL
Vec-tor	NULL
Laboratories	NULL
,	NULL
from	NULL
Dako	NULL
)	NULL
.	NULL

Additional	NULL
controls	NULL
were	NULL
performed	NULL
by	NULL
fluorescence	NULL
activated	NULL
flow	NULL
cytometry	NULL
(	NULL
FACS	NULL
)	NULL
using	NULL
the	NULL
FITC-Leu-M3	NULL
antibody	NULL
(	NULL
Becton-Dickinson	NULL
,	NULL
Moun-tainview	NULL
,	NULL
CA	NULL
,	NULL
USA	NULL
)	NULL
.	NULL

Contamination	NULL
of	NULL
epithelial	NULL
cells	NULL
was	NULL
found	NULL
to	NULL
be	NULL
less	NULL
than	NULL
0.5	NULL
%	NULL
by	NULL
both	NULL
morphological	NULL
examination	NULL
and	NULL
cytokeratin	NULL
antibody	NULL
(	NULL
Dako	NULL
)	NULL
staining	NULL
.	NULL

The	NULL
percentage	NULL
of	NULL
macrophages	NULL
,	NULL
CD4	NULL
T	NULL
cells	NULL
,	NULL
CD8	NULL
T	NULL
cells	NULL
,	NULL
and	NULL
B	NULL
479	NULL
cells	NULL
found	NULL
was	NULL
similar	NULL
to	NULL
that	NULL
described	NULL
in	NULL
earlier	NULL
flow	NULL
cytometric	NULL
studies	NULL
.	NULL
``	NULL

CELL	NULL
CULTURES	NULL
AND	NULL
CYTOKINE	NULL
ASSAYS	NULL
Cells	NULL
were	NULL
cultured	NULL
at	NULL
a	NULL
concentration	NULL
of	NULL
1	NULL
x	NULL
10®/ml	NULL
in	NULL
RPMI	NULL
1640	NULL
(	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
,	NULL
1	NULL
%	NULL
pyruvate	NULL
,	NULL
100	NULL
U/ml	NULL
penicillin	NULL
,	NULL
and	NULL
50	NULL
ug/ml	NULL
gentamicin	NULL
)	NULL
.	NULL

After	NULL
24	NULL
hours	NULL
,	NULL
supernatants	NULL
were	NULL
separated	NULL
from	NULL
cells	NULL
by	NULL
centrifugation	NULL
,	NULL
snap	NULL
frozen	NULL
and	NULL
stored	NULL
at	NULL
-70°C	NULL
until	NULL
determination	NULL
of	NULL
cytokine	NULL
levels	NULL
.	NULL

Supernatant	NULL
concentrations	NULL
of	NULL
TNF-a	NULL
,	NULL
IL-18	NULL
and	NULL
IL-1ra	NULL
were	NULL
assessed	NULL
using	NULL
a	NULL
specific	NULL
sandwich	NULL
ELISA	NULL
.	NULL

All	NULL
samples	NULL
were	NULL
analysed	NULL
in	NULL
triplicate	NULL
or	NULL
duplicate	NULL
.	NULL

The	NULL
amount	NULL
of	NULL
cross	NULL
reactivity	NULL
was	NULL
assessed	NULL
by	NULL
comparison	NULL
with	NULL
the	NULL
concentration	NULL
yielding	NULL
a	NULL
50	NULL
%	NULL
inhibition	NULL
of	NULL
binding	NULL
.	NULL

Specificity	NULL
of	NULL
the	NULL
ELISAs	NULL
was	NULL
demonstrated	NULL
by	NULL
the	NULL
finding	NULL
that	NULL
up	NULL
to	NULL
100	NULL
pg/ml	NULL
IL-1	NULL
,	NULL
IL-2	NULL
,	NULL
IL-3	NULL
,	NULL
IL-4	NULL
,	NULL
IL-5	NULL
,	NULL
IL-6	NULL
,	NULL
IL-8	NULL
,	NULL
IL-10	NULL
,	NULL
IL-12	NULL
,	NULL
granulocyte	NULL
colony	NULL
stimulating	NULL
factor	NULL
,	NULL
granulocyte-macrophage	NULL
colony	NULL
stimulating	NULL
factor	NULL
,	NULL
and	NULL
TNF-a	NULL
showed	NULL
no	NULL
significant	NULL
cross	NULL
reactivity	NULL
or	NULL
interference	NULL
.	NULL

Sensitivity	NULL
levels	NULL
were	NULL
between	NULL
2.0	NULL
pg/ml	NULL
(	NULL
IL-18	NULL
)	NULL
and	NULL
4.0	NULL
pg/ml	NULL
(	NULL
TNF-a	NULL
)	NULL
,	NULL
and	NULL
intra-	NULL
and	NULL
inter-assay	NULL
precision	NULL
variability	NULL
was	NULL
below	NULL
3	NULL
%	NULL
.	NULL
``	NULL

Repeated	NULL
thawing	NULL
and	NULL
freezing	NULL
of	NULL
the	NULL
cultured	NULL
cells	NULL
,	NULL
which	NULL
would	NULL
release	NULL
cytokines	NULL
stored	NULL
in	NULL
the	NULL
cytoplasm	NULL
,	NULL
did	NULL
not	NULL
increase	NULL
the	NULL
cytokine	NULL
levels	NULL
significantly	NULL
.	NULL

Therefore	NULL
all	NULL
cytokines	NULL
synthesised	NULL
were	NULL
secreted	NULL
into	NULL
the	NULL
supernatant	NULL
.	NULL

For	NULL
analysis	NULL
of	NULL
transcription	NULL
factor	NULL
activation	NULL
,	NULL
cells	NULL
from	NULL
patients	NULL
with	NULL
IBD	NULL
and	NULL
normal	NULL
control	NULL
cells	NULL
were	NULL
incubated	NULL
for	NULL
15-90	NULL
minutes	NULL
with	NULL
LPS	NULL
(	NULL
1	NULL
ug/tal	NULL
)	NULL
.	NULL

EXTRACTS	NULL
Biopsy	NULL
samples	NULL
were	NULL
snap	NULL
frozen	NULL
in	NULL
liquid	NULL
nitrogen	NULL
at	NULL
the	NULL
time	NULL
of	NULL
removal	NULL
and	NULL
later	NULL
mechanically	NULL
homogenised	NULL
in	NULL
liquid	NULL
nitrogen	NULL
(	NULL
Dounce	NULL
homogeniser	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
pelleted	NULL
and	NULL
immediately	NULL
fractionated	NULL
.	NULL

Nuclear	NULL
and	NULL
cytosolic	NULL
extracts	NULL
respectively	NULL
were	NULL
prepared	NULL
by	NULL
adaptation	NULL
of	NULL
previously	NULL
described	NULL
techniques	NULL
through	NULL
freeze/thaw	NULL
cycles	NULL
between	NULL
crushed	NULL
ice	NULL
and	NULL
liquid	NULL
nitrogen	NULL
.	NULL
``	NULL

**	NULL
Cytosolic	NULL
extracts	NULL
were	NULL
collected	NULL
in	NULL
an	NULL
aqueous	NULL
buffer	NULL
containing	NULL
10	NULL
mM	NULL
Hepes	NULL
(	NULL
pH	NULL
7.9	NULL
)	NULL
,	NULL
1.5	NULL
mM	NULL
MgCl	NULL
,	NULL
,	NULL
and	NULL
10	NULL
mM	NULL
KCI	NULL
Nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
by	NULL
solubilising	NULL
the	NULL
remaining	NULL
nuclei	NULL
in	NULL
a	NULL
second	NULL
buffer	NULL
containing	NULL
20	NULL
mM	NULL
Hepes	NULL
(	NULL
pH	NULL
7.9	NULL
)	NULL
,	NULL
420	NULL
mM	NULL
NaCl	NULL
,	NULL
1.5	NULL
mM	NULL
MgCl	NULL
,	NULL
,	NULL
0.2	NULL
mM	NULL
EDTA	NULL
,	NULL
and	NULL
25	NULL
%	NULL
glycerol	NULL
.	NULL

Both	NULL
buffers	NULL
were	NULL
supplemented	NULL
with	NULL
1	NULL
mM	NULL
dithiothreitol	NULL
,	NULL
0.5	NULL
mM	NULL
phenylmethanesulphonyl	NULL
fluoride	NULL
,	NULL
1	NULL
pg/ml	NULL
aprotinin	NULL
,	NULL
1	NULL
ug/ml	NULL
leupeptin	NULL
,	NULL
1	NULL
ug/ml	NULL
pepstatin	NULL
,	NULL
1	NULL
mM	NULL
benzamidine	NULL
,	NULL
1	NULL
mM	NULL
sodium	NULL
vanadate	NULL
,	NULL
and	NULL
1	NULL
mM	NULL
NaF	NULL
.	NULL

The	NULL
purity	NULL
of	NULL
the	NULL
extract	NULL
fractions	NULL
was	NULL
tested	NULL
by	NULL
marker	NULL
proteins	NULL
exclusively	NULL
expressed	NULL
in	NULL
one	NULL
of	NULL
the	NULL
compartments	NULL
(	NULL
IxBa	NULL
and	NULL
fructose	NULL
aldolase	NULL
as	NULL
markers	NULL
for	NULL
the	NULL
cytosol	NULL
and	NULL
OCT-1	NULL
as	NULL
a	NULL
nuclear	NULL
marker	NULL
)	NULL
.	NULL
``	NULL

``	NULL
``	NULL
For	NULL
the	NULL
assessment	NULL
of	NULL
total	NULL
expression	NULL
levels	NULL
of	NULL
the	NULL
proteins	NULL
studied	NULL
,	NULL
western	NULL
blot	NULL
experiments	NULL
were	NULL
performed	NULL
utilising	NULL
snap	NULL
frozen	NULL
cell	NULL
pellets	NULL
or	NULL
homogenised	NULL
biopsy	NULL
specimens	NULL
which	NULL
were	NULL
lysed	NULL
in	NULL
boiling	NULL
extraction	NULL
buffer	NULL
(	NULL
1	NULL
%	NULL
sodium	NULL
dodecyl	NULL
sulphate	NULL
,	NULL
10	NULL
mM	NULL
Tris	NULL
,	NULL
pH	NULL
7.5	NULL
,	NULL
1	NULL
mM	NULL
sodium	NULL
vanadate	NULL
)	NULL
.	NULL

Insoluble	NULL
material	NULL
was	NULL
480	NULL
&	NULL
A	NULL
Narmal	NULL
Ulcerstive	NULL
Crolan	NULL
's	NULL
dissase	NULL
CoN	NULL
OC	NULL
bo	NULL
to	NULL
W	NULL
W	NULL
“	NULL
Hi	NULL
“	NULL
W	NULL
Free	NULL
_	NULL
L_	NULL
__	NULL
Schreiber	NULL
,	NULL
Nikolaus	NULL
,	NULL
Hampe	NULL
sit=	NULL
BJFi	NULL
;	NULL
E	NULL
)	NULL
e	NULL
A	NULL
-	NULL
#	NULL
-	NULL
Nuclear	NULL
pS	NULL
Figure	NULL
3	NULL
-	NULL
Detection	NULL
of	NULL
NFKB	NULL
in	NULL
the	NULL
intestinal	NULL
lamina	NULL
propria	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
from	NULL
colonoscopic	NULL
biopsy	NULL
specimens	NULL
.	NULL

A	NULL
representative	NULL
radioactive	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
assay	NULL
using	NULL
consensus	NULL
oligonucleotides	NULL
to	NULL
detect	NULL
NFKB	NULL
in	NULL
nuclear	NULL
extracts	NULL
from	NULL
intestinal	NULL
tissue	NULL
is	NULL
shown	NULL
.	NULL

In	NULL
both	NULL
Crohn	NULL
's	NULL
disease	NULL
(	NULL
n	NULL
=	NULL
9	NULL
)	NULL
and	NULL
ulcerative	NULL
colitis	NULL
(	NULL
n	NULL
=	NULL
8	NULL
)	NULL
increased	NULL
levels	NULL
of	NULL
NFKB	NULL
were	NULL
found	NULL
in	NULL
comparison	NULL
with	NULL
disease	NULL
specificity	NULL
controls	NULL
(	NULL
n	NULL
=	NULL
5	NULL
)	NULL
and	NULL
healthy	NULL
volunteers	NULL
(	NULL
n	NULL
=	NULL
8	NULL
)	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
from	NULL
LPMNCs	NULL
,	NULL
which	NULL
were	NULL
freshly	NULL
isolated	NULL
from	NULL
colonic	NULL
biopsy	NULL
specimens	NULL
.	NULL

A	NULL
blot	NULL
from	NULL
a	NULL
representative	NULL
non-radioactive	NULL
gel	NULL
shift	NULL
experiment	NULL
with	NULL
ten	NULL
samples	NULL
(	NULL
C	NULL
=	NULL
Crohn	NULL
's	NULL
disease	NULL
;	NULL
U	NULL
=	NULL
ulcerative	NULL
colitis	NULL
;	NULL
D	NULL
=	NULL
disease	NULL
specificity	NULL
controls	NULL
;	NULL
N	NULL
=	NULL
normal	NULL
controls	NULL
)	NULL
is	NULL
shown	NULL
.	NULL

The	NULL
highest	NULL
levels	NULL
of	NULL
activated	NULL
NFKB	NULL
were	NULL
seen	NULL
in	NULL
patients	NULL
with	NULL
active	NULL
Crohn	NULL
's	NULL
disease	NULL
,	NULL
with	NULL
similar	NULL
levels	NULL
in	NULL
all	NULL
four	NULL
samples	NULL
.	NULL

In	NULL
only	NULL
one	NULL
of	NULL
four	NULL
normal	NULL
control	NULL
samples	NULL
could	NULL
low	NULL
levels	NULL
of	NULL
oligonucleotide	NULL
binding	NULL
proteins	NULL
be	NULL
detected	NULL
.	NULL

Levels	NULL
in	NULL
patients	NULL
with	NULL
ulcerative	NULL
colitis	NULL
(	NULL
four	NULL
)	NULL
as	NULL
well	NULL
as	NULL
disease	NULL
specificity	NULL
controls	NULL
(	NULL
three	NULL
)	NULL
appeared	NULL
to	NULL
be	NULL
increased	NULL
as	NULL
well	NULL
,	NULL
although	NULL
not	NULL
as	NULL
much	NULL
as	NULL
in	NULL
Crohn	NULL
's	NULL
disease	NULL
.	NULL

The	NULL
presence	NULL
of	NULL
NFKB	NULL
p65	NULL
as	NULL
part	NULL
of	NULL
the	NULL
complex	NULL
was	NULL
controlled	NULL
by	NULL
supershift	NULL
experiments	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
levels	NULL
of	NULL
nuclear	NULL
p65	NULL
determined	NULL
in	NULL
the	NULL
same	NULL
extracts	NULL
by	NULL
western	NULL
blot	NULL
are	NULL
shown	NULL
in	NULL
the	NULL
lower	NULL
part	NULL
of	NULL
the	NULL
figure	NULL
.	NULL

removed	NULL
by	NULL
centrifugation	NULL
of	NULL
samples	NULL
for	NULL
20	NULL
minutes	NULL
at	NULL
27	NULL
000	NULL
g.	NULL
Total	NULL
protein	NULL
concentration	NULL
in	NULL
a	NULL
small	NULL
aliquot	NULL
of	NULL
sample	NULL
was	NULL
assessed	NULL
using	NULL
either	NULL
the	NULL
method	NULL
of	NULL
Lowry	NULL
or	NULL
a	NULL
modified	NULL
Bradford	NULL
protein	NULL
assay	NULL
(	NULL
Bio-Rad	NULL
,	NULL
Munich	NULL
,	NULL
Germany	NULL
)	NULL
,	NULL
and	NULL
all	NULL
samples	NULL
were	NULL
adjusted	NULL
to	NULL
an	NULL
equal	NULL
protein	NULL
content	NULL
before	NULL
analysis	NULL
.	NULL
``	NULL

In	NULL
addition	NULL
,	NULL
equal	NULL
loading	NULL
of	NULL
proteins	NULL
was	NULL
controlled	NULL
by	NULL
total	NULL
protein	NULL
staining	NULL
of	NULL
all	NULL
membranes	NULL
with	NULL
colloidal	NULL
gold	NULL
(	NULL
Bio-Rad	NULL
,	NULL
Hercules	NULL
,	NULL
CA	NULL
,	NULL
USA	NULL
)	NULL
.	NULL
``	NULL

Only	NULL
membranes	NULL
with	NULL
equal	NULL
amounts	NULL
of	NULL
protein	NULL
loaded	NULL
were	NULL
used	NULL
for	NULL
analysis	NULL
.	NULL

In	NULL
parallel	NULL
,	NULL
total	NULL
histone	NULL
protein	NULL
was	NULL
assessed	NULL
in	NULL
nuclear	NULL
extracts	NULL
(	NULL
antibody	NULL
from	NULL
Boehringer-Mannheim	NULL
)	NULL
,	NULL
and	NULL
found	NULL
to	NULL
yield	NULL
results	NULL
identical	NULL
with	NULL
those	NULL
from	NULL
total	NULL
protein	NULL
staining	NULL
.	NULL

EMSA	NULL
FOR	NULL
THE	NULL
DETECTION	NULL
OF	NULL
SPECIFIC	NULL
OLIGONUCLEOTIDE	NULL
BINDING	NULL
OF	NULL
ACTIVATED	NULL
NFKB	NULL
EMSA	NULL
was	NULL
used	NULL
to	NULL
detect	NULL
specific	NULL
binding	NULL
of	NULL
activated	NULL
NFxB	NULL
by	NULL
the	NULL
formation	NULL
of	NULL
DNA	NULL
complexes	NULL
.	NULL
``	NULL

*	NULL
*	NULL
``	NULL
Nuclear	NULL
protein-DNA	NULL
binding	NULL
studies	NULL
were	NULL
carried	NULL
out	NULL
for	NULL
30	NULL
minutes	NULL
at	NULL
24°C	NULL
in	NULL
a	NULL
20	NULL
pul	NULL
reaction	NULL
volume	NULL
containing	NULL
20	NULL
mM	NULL
Hepes	NULL
,	NULL
pH	NULL
7.9	NULL
,	NULL
10	NULL
%	NULL
glycerol	NULL
,	NULL
5	NULL
mM	NULL
MgCl	NULL
,	NULL
,	NULL
0.1	NULL
mM	NULL
EDTA	NULL
,	NULL
0.5	NULL
mM	NULL
dithiothreitol	NULL
,	NULL
lug	NULL
poly	NULL
(	NULL
dI-dC	NULL
)	NULL
,	NULL
1	NULL
fmol	NULL
digoxigenin-labelled	NULL
DNA	NULL
probe	NULL
,	NULL
and	NULL
5	NULL
ug	NULL
nuclear	NULL
protein	NULL
.	NULL

Gel	NULL
electro-phoresis	NULL
was	NULL
performed	NULL
as	NULL
described	NULL
by	NULL
Hou	NULL
et	NULL
aP	NULL
``	NULL
in	NULL
an	NULL
adaptation	NULL
of	NULL
methods	NULL
described	NULL
previously	NULL
.	NULL
``	NULL

*	NULL
A	NULL
DNA	NULL
probe	NULL
,	NULL
as	NULL
described	NULL
pre-viously	NULL
,	NULL
was	NULL
prepared	NULL
by	NULL
annealing	NULL
the	NULL
following	NULL
two	NULL
consensus	NULL
oligonucleotides	NULL
,	NULL
``	NULL
which	NULL
were	NULL
labelled	NULL
at	NULL
the	NULL
5°	NULL
end	NULL
with	NULL
digoxigenin	NULL
(	NULL
Biometra	NULL
,	NULL
-	NULL
Mannheim	NULL
,	NULL
Germany	NULL
-	NULL
and	NULL
Boehringer-Mannheim	NULL
)	NULL
:	NULL
(	NULL
S-AGT	NULL
TGA	NULL
GGG	NULL
GAC	NULL
TTT	NULL
CCC	NULL
AGG	NULL
C-3	NULL
'	NULL
@	NULL
)	NULL
3-TCA	NULL
ACT	NULL
CCC	NULL
CTG	NULL
AAA	NULL
GGG	NULL
TCC	NULL
G-5	NULL
'	NULL
.	NULL

A	NULL
6	NULL
%	NULL
non-denaturing	NULL
polyacrylamide	NULL
gel	NULL
was	NULL
used	NULL
for	NULL
electrophoretic	NULL
separation	NULL
.	NULL

DNA	NULL
probes	NULL
bound	NULL
to	NULL
NFxB	NULL
were	NULL
retarded	NULL
,	NULL
whereas	NULL
unbound	NULL
(	NULL
free	NULL
)	NULL
DNA	NULL
probes	NULL
migrated	NULL
to	NULL
the	NULL
bottom	NULL
of	NULL
the	NULL
electropherogram	NULL
.	NULL

Supershift	NULL
assays	NULL
with	NULL
a	NULL
polyclonal	NULL
p65	NULL
antibody	NULL
were	NULL
carried	NULL
out	NULL
to	NULL
confirm	NULL
the	NULL
presence	NULL
of	NULL
NFxB	NULL
p65	NULL
as	NULL
part	NULL
of	NULL
the	NULL
complex	NULL
.	NULL

After	NULL
blotting	NULL
to	NULL
a	NULL
membrane	NULL
,	NULL
labelled	NULL
oligonucleotides	NULL
were	NULL
detected	NULL
by	NULL
alkaline	NULL
phosphatase	NULL
anti-digoxigenin	NULL
(	NULL
Fab	NULL
)	NULL
,	NULL
fragments	NULL
(	NULL
Boehringer-Mannheim	NULL
)	NULL
.	NULL

In	NULL
some	NULL
experiments	NULL
oligonucleotides	NULL
were	NULL
labelled	NULL
with	NULL
[	NULL
P	NULL
]	NULL
dATP	NULL
using	NULL
a	NULL
random	NULL
primed	NULL
DNA	NULL
labelling	NULL
kit	NULL
from	NULL
Boehringer-Mannheim	NULL
.	NULL

Radioactive	NULL
gels	NULL
were	NULL
fixed	NULL
in	NULL
an	NULL
aqueous	NULL
solution	NULL
of	NULL
10	NULL
%	NULL
ethanol	NULL
and	NULL
10	NULL
%	NULL
acetic	NULL
acid	NULL
before	NULL
being	NULL
dried	NULL
by	NULL
heat	NULL
exposure	NULL
.	NULL

It	NULL
was	NULL
found	NULL
that	NULL
the	NULL
non-radioactive	NULL
detection	NULL
system	NULL
established	NULL
was	NULL
equal	NULL
in	NULL
sensitivity	NULL
and	NULL
specificity	NULL
to	NULL
conventional	NULL
radiola-belled	NULL
oligonucleotides	NULL
.	NULL

WESTERN	NULL
BLOT	NULL
ASSESSMENT	NULL
OF	NULL
NFKB	NULL
P65	NULL
AND	NULL
IKB	NULL
A	NULL
5-15	NULL
pul	NULL
volume	NULL
of	NULL
cell	NULL
lysate	NULL
(	NULL
5-10	NULL
ug	NULL
total	NULL
protein	NULL
)	NULL
was	NULL
separated	NULL
on	NULL
a	NULL
12	NULL
%	NULL
denaturing	NULL
polyacrylamide	NULL
gel	NULL
.	NULL

Separated	NULL
proteins	NULL
were	NULL
transferred	NULL
to	NULL
a	NULL
polyvinylidene	NULL
difluoride	NULL
membrane	NULL
(	NULL
20	NULL
V	NULL
;	NULL
75	NULL
minutes	NULL
;	NULL
transfer	NULL
buffer	NULL
25	NULL
mM	NULL
Tris	NULL
,	NULL
190	NULL
mM	NULL
glycine	NULL
,	NULL
20	NULL
%	NULL
methanol	NULL
,	NULL
0.5	NULL
%	NULL
sodium	NULL
dodecyl	NULL
sulphate	NULL
)	NULL
by	NULL
electroblotter	NULL
(	NULL
Bio-Rad	NULL
,	NULL
Hercules	NULL
,	NULL
CA	NULL
,	NULL
USA	NULL
)	NULL
.	NULL

The	NULL
membrane	NULL
was	NULL
placed	NULL
into	NULL
blocking	NULL
buffer	NULL
(	NULL
5	NULL
%	NULL
non-fat	NULL
milk	NULL
in	NULL
10	NULL
mM	NULL
Tris/HCl	NULL
,	NULL
pH	NULL
7.5	NULL
,	NULL
100	NULL
mM	NULL
NaCl	NULL
,	NULL
0.1	NULL
%	NULL
Tween	NULL
20	NULL
)	NULL
for	NULL
one	NULL
hour	NULL
at	NULL
room	NULL
temperature	NULL
.	NULL

Blocking	NULL
buffer	NULL
was	NULL
decanted	NULL
and	NULL
the	NULL
membrane	NULL
was	NULL
incubated	NULL
with	NULL
primary	NULL
antibody	NULL
(	NULL
diluted	NULL
in	NULL
blocking	NULL
buffer	NULL
)	NULL
on	NULL
a	NULL
shaker	NULL
at	NULL
room	NULL
temperature	NULL
(	NULL
one	NULL
hour	NULL
)	NULL
.	NULL

After	NULL
being	NULL
washed	NULL
(	NULL
10	NULL
mM	NULL
Tris/HCl	NULL
,	NULL
pH	NULL
7.5	NULL
,	NULL
100	NULL
mM	NULL
NaCl	NULL
,	NULL
0.1	NULL
%	NULL
Tween	NULL
20	NULL
)	NULL
,	NULL
the	NULL
membrane	NULL
was	NULL
incubated	NULL
with	NULL
a	NULL
peroxidase	NULL
conjugated	NULL
secondary	NULL
antibody	NULL
,	NULL
which	NULL
was	NULL
diluted	NULL
in	NULL
5	NULL
%	NULL
non-fat	NULL
milk	NULL
in	NULL
wash	NULL
buffer	NULL
(	NULL
one	NULL
hour	NULL
;	NULL
room	NULL
temperature	NULL
;	NULL
gentle	NULL
shaking	NULL
)	NULL
.	NULL

After	NULL
being	NULL
washed	NULL
,	NULL
the	NULL
membrane	NULL
was	NULL
placed	NULL
in	NULL
a	NULL
hybridi-sation	NULL
bag	NULL
containing	NULL
Western	NULL
View	NULL
(	NULL
Dianova/	NULL
Transduction	NULL
Laboratories	NULL
)	NULL
working	NULL
solution	NULL
.	NULL

The	NULL
bands	NULL
were	NULL
quantified	NULL
by	NULL
densitometry	NULL
NFB	NULL
in	NULL
inflammatory	NULL
bowel	NULL
disease	NULL
481	NULL
Table	NULL
2	NULL
-	NULL
Down-regulation	NULL
of	NULL
pro-inflammatory	NULL
cytokine	NULL
secretion	NULL
by	NULL
specific	NULL
inhibition	NULL
of	NULL
NFKB	NULL
activation	NULL
TNF-a	NULL
(	NULL
pg/ml	NULL
)	NULL
IL-18	NULL
(	NULL
pg/ml	NULL
)	NULL
Cell	NULL
type	NULL
Source	NULL
Control	NULL
Dexamethasone	NULL
TPCK	NULL
Control	NULL
Dexamethasone	NULL
TPCK	NULL
LPMNC	NULL
CD	NULL
274	NULL
45	NULL
112	NULL
221	NULL
31	NULL
137	NULL
LPMNC	NULL
CD	NULL
412	NULL
54	NULL
31	NULL
145	NULL
56	NULL
67	NULL
LPMNC	NULL
UC	NULL
232	NULL
19	NULL
177	NULL
267	NULL
27	NULL
12	NULL
LPMNC	NULL
UC	NULL
376	NULL
81	NULL
58	NULL
172	NULL
47	NULL
154	NULL
LPMNC	NULL
NC	NULL
112	NULL
71	NULL
22	NULL
154	NULL
0	NULL
0	NULL
LPMNC	NULL
NC	NULL
72	NULL
0	NULL
18	NULL
67	NULL
27	NULL
15	NULL
All	NULL
cells	NULL
were	NULL
stimulated	NULL
with	NULL
LPS/pokeweed	NULL
mitogen	NULL
with	NULL
or	NULL
without	NULL
the	NULL
simultaneous	NULL
addition	NULL
of	NULL
TPCK	NULL
(	NULL
30	NULL
uM	NULL
)	NULL
or	NULL
dexamethasone	NULL
(	NULL
107°	NULL
M	NULL
)	NULL
.	NULL

In	NULL
parallel	NULL
,	NULL
activation	NULL
of	NULL
NFxB	NULL
was	NULL
determined	NULL
in	NULL
nuclear	NULL
extracts	NULL
30	NULL
minutes	NULL
after	NULL
stimulation	NULL
by	NULL
gel	NULL
shift	NULL
(	NULL
fig	NULL
4	NULL
)	NULL
.	NULL

(	NULL
Lumi-Imager	NULL
;	NULL
Boehringer-Mannheim	NULL
)	NULL
.	NULL

Equal	NULL
loading	NULL
of	NULL
gels	NULL
was	NULL
controlled	NULL
by	NULL
assessing	NULL
total	NULL
protein	NULL
staining	NULL
of	NULL
all	NULL
membranes	NULL
with	NULL
colloidal	NULL
gold	NULL
.	NULL
``	NULL

EXPRESSION	NULL
OF	NULL
DATA	NULL
Results	NULL
are	NULL
expressed	NULL
as	NULL
mean	NULL
(	NULL
SD	NULL
)	NULL
if	NULL
not	NULL
indicated	NULL
otherwise	NULL
.	NULL

All	NULL
experiments	NULL
were	NULL
carried	NULL
out	NULL
three	NULL
or	NULL
more	NULL
times	NULL
.	NULL

Normal	NULL
distribution	NULL
of	NULL
data	NULL
was	NULL
evaluated	NULL
by	NULL
calculating	NULL
Lilliefors	NULL
probabilities	NULL
based	NULL
on	NULL
the	NULL
Kolmogorov-Smirnov	NULL
test	NULL
.	NULL
``	NULL

*	NULL
Statistical	NULL
significance	NULL
of	NULL
the	NULL
differences	NULL
for	NULL
non-normally	NULL
distributed	NULL
data	NULL
was	NULL
tested	NULL
with	NULL
the	NULL
Mann	NULL
Whitney	NULL
U	NULL
test	NULL
or	NULL
the	NULL
Wilcoxon	NULL
matched	NULL
pairs	NULL
test	NULL
.	NULL
``	NULL

*	NULL
+	NULL
TPEK	NULL
L	NULL
%	NULL
x	NULL
i	NULL
uo	NULL
p	NULL
c	NULL
LPS	NULL
Figure	NULL
4	NULL
-	NULL
Inhibition	NULL
of	NULL
NFKB	NULL
activation	NULL
(	NULL
A	NULL
)	NULL
and	NULL
IxBa	NULL
degradation	NULL
(	NULL
B	NULL
)	NULL
by	NULL
steroids	NULL
(	NULL
dexamethasone	NULL
)	NULL
and	NULL
N-a-tosyl-phenylalanine	NULL
chloromethyl	NULL
ketone	NULL
(	NULL
TPCK	NULL
)	NULL
.	NULL

Nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
from	NULL
lamnia	NULL
propria	NULL
lear	NULL
cells	NULL
obtained	NULL
from	NULL
col	NULL
opic	NULL
biopsy	NULL
samples	NULL
(	NULL
two	NULL
patients	NULL
with	NULL
Crohn	NULL
's	NULL
disease	NULL
and	NULL
two	NULL
normal	NULL
volunteer	NULL
controls	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
cultured	NULL
for	NULL
30	NULL
minutes	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
lipopolysaccharide	NULL
(	NULL
LPS	NULL
)	NULL
.	NULL

A	NULL
representative	NULL
blot	NULL
from	NULL
a	NULL
patient	NULL
with	NULL
Crohn	NULL
's	NULL
disease	NULL
is	NULL
shown	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Both	NULL
dexamethasone	NULL
(	NULL
10	NULL
uM	NULL
)	NULL
and	NULL
TPCK	NULL
(	NULL
30	NULL
uM	NULL
)	NULL
strongly	NULL
reduced	NULL
the	NULL
s	NULL
of	NULL
NFB	NULL
ilable	NULL
for	NULL
binding	NULL
to	NULL
consensus	NULL
oligonucleotides	NULL
.	NULL

(	NULL
B	NULL
)	NULL
IxBa	NULL
was	NULL
assessed	NULL
in	NULL
total	NULL
extracts	NULL
by	NULL
western	NULL
blot	NULL
.	NULL

TPCK	NULL
as	NULL
well	NULL
as	NULL
dexamethasone	NULL
stabilised	NULL
IxBa	NULL
against	NULL
activation	NULL
induced	NULL
degradation	NULL
.	NULL

Results	NULL
INCREASED	NULL
EXPRESSION	NULL
OF	NULL
NFKB	NULL
P65	NULL
IN	NULL
NUCLEAR	NULL
EXTRACTS	NULL
FROM	NULL
COLONIC	NULL
BIOPSY	NULL
SAMPLES	NULL
OF	NULL
PATIENTS	NULL
WITH	NULL
IBD	NULL
Nuclear	NULL
protein	NULL
from	NULL
colonic	NULL
biopsy	NULL
samples	NULL
was	NULL
extracted	NULL
.	NULL

Nuclear	NULL
levels	NULL
of	NULL
NFB	NULL
p65	NULL
protein	NULL
were	NULL
evaluated	NULL
by	NULL
western	NULL
blot	NULL
in	NULL
colonic	NULL
biopsy	NULL
samples	NULL
of	NULL
ten	NULL
patients	NULL
with	NULL
active	NULL
Crohn	NULL
's	NULL
disease	NULL
,	NULL
14	NULL
patients	NULL
with	NULL
active	NULL
ulcerative	NULL
colitis	NULL
,	NULL
six	NULL
disease	NULL
specificity	NULL
controls	NULL
,	NULL
and	NULL
seven	NULL
normal	NULL
controls	NULL
(	NULL
table	NULL
1	NULL
)	NULL
.	NULL

Samples	NULL
were	NULL
diluted	NULL
to	NULL
equal	NULL
concentrations	NULL
of	NULL
total	NULL
protein	NULL
before	NULL
analysis	NULL
.	NULL

Patients	NULL
with	NULL
Crohn	NULL
's	NULL
disease	NULL
exhibited	NULL
higher	NULL
levels	NULL
of	NULL
nuclear	NULL
NFxB	NULL
p65	NULL
than	NULL
those	NULL
with	NULL
ulcerative	NULL
colitis	NULL
(	NULL
p	NULL
=	NULL
0.035	NULL
)	NULL
,	NULL
disease	NULL
specificity	NULL
controls	NULL
(	NULL
p	NULL
=	NULL
0.0312	NULL
)	NULL
,	NULL
and	NULL
normal	NULL
volunteers	NULL
(	NULL
p	NULL
=	NULL
0.0012	NULL
)	NULL
.	NULL

In	NULL
patients	NULL
with	NULL
ulcerative	NULL
colitis	NULL
,	NULL
more	NULL
nuclear	NULL
NFxB	NULL
p65	NULL
was	NULL
found	NULL
than	NULL
in	NULL
normal	NULL
controls	NULL
(	NULL
p	NULL
=	NULL
0.038	NULL
)	NULL
,	NULL
but	NULL
no	NULL
statistical	NULL
difference	NULL
was	NULL
seen	NULL
in	NULL
comparison	NULL
with	NULL
disease	NULL
specificity	NULL
controls	NULL
.	NULL

The	NULL
increased	NULL
expression	NULL
of	NULL
nuclear	NULL
NFxB	NULL
p65	NULL
in	NULL
disease	NULL
specificity	NULL
controls	NULL
did	NULL
not	NULL
reach	NULL
significance	NULL
in	NULL
comparison	NULL
with	NULL
normal	NULL
controls	NULL
(	NULL
fig	NULL
1	NULL
)	NULL
.	NULL

Alternatively	NULL
,	NULL
biopsy	NULL
specimens	NULL
from	NULL
the	NULL
same	NULL
sites	NULL
were	NULL
homogenised	NULL
for	NULL
the	NULL
assessment	NULL
of	NULL
total	NULL
tissue	NULL
concentrations	NULL
of	NULL
NFxB	NULL
p65	NULL
protein	NULL
.	NULL

Total	NULL
levels	NULL
of	NULL
NFxB	NULL
p65	NULL
were	NULL
not	NULL
different	NULL
in	NULL
patients	NULL
with	NULL
Crohn	NULL
's	NULL
disease	NULL
,	NULL
those	NULL
with	NULL
ulcerative	NULL
colitis	NULL
,	NULL
normal	NULL
controls	NULL
,	NULL
and	NULL
disease	NULL
specificity	NULL
controls	NULL
(	NULL
fig	NULL
2	NULL
)	NULL
,	NULL
and	NULL
no	NULL
differences	NULL
in	NULL
IxBa	NULL
levels	NULL
were	NULL
seen	NULL
between	NULL
the	NULL
groups	NULL
(	NULL
fig	NULL
2	NULL
)	NULL
.	NULL

DNA	NULL
BINDING	NULL
OF	NULL
NUCLEAR	NULL
NFKB	NULL
IS	NULL
INCREASED	NULL
IN	NULL
EXTRACTS	NULL
FROM	NULL
LAMINA	NULL
PROPRIA	NULL
BIOPSY	NULL
SAMPLES	NULL
AS	NULL
WELL	NULL
AS	NULL
IN	NULL
LPMNCS	NULL
ISOLATED	NULL
FROM	NULL
COLONIC	NULL
BIOPSY	NULL
SPECIMENS	NULL
FROM	NULL
PATIENTS	NULL
WITH	NULL
IBD	NULL
The	NULL
increased	NULL
levels	NULL
of	NULL
NFB	NULL
p65	NULL
in	NULL
nuclear	NULL
extracts	NULL
in	NULL
Crohn	NULL
's	NULL
disease	NULL
indicate	NULL
that	NULL
there	NULL
may	NULL
also	NULL
be	NULL
increased	NULL
amounts	NULL
of	NULL
NFxB	NULL
dimers	NULL
which	NULL
are	NULL
capable	NULL
of	NULL
specific	NULL
binding	NULL
to	NULL
consensus	NULL
oligonucleotides	NULL
.	NULL

Figure	NULL
3	NULL
shows	NULL
a	NULL
representative	NULL
gel	NULL
shift	NULL
experiment	NULL
demonstrating	NULL
increased	NULL
amounts	NULL
of	NULL
DNA	NULL
binding	NULL
of	NULL
NFxB	NULL
in	NULL
nuclear	NULL
extracts	NULL
from	NULL
biopsy	NULL
specimens	NULL
(	NULL
fig	NULL
3A	NULL
)	NULL
as	NULL
well	NULL
as	NULL
isolated	NULL
LPMNCs	NULL
(	NULL
fig	NULL
3B	NULL
)	NULL
.	NULL

In	NULL
all	NULL
Crohn	NULL
's	NULL
disease	NULL
biopsy	NULL
samples	NULL
as	NULL
well	NULL
as	NULL
unstimulated	NULL
LPMNCs	NULL
,	NULL
greatly	NULL
increased	NULL
levels	NULL
of	NULL
nuclear	NULL
NFB	NULL
could	NULL
be	NULL
detected	NULL
by	NULL
its	NULL
specific	NULL
oligonucleotide	NULL
binding	NULL
activity	NULL
.	NULL

In	NULL
contrast	NULL
with	NULL
normal	NULL
controls	NULL
,	NULL
most	NULL
patients	NULL
with	NULL
ulcerative	NULL
colitis	NULL
also	NULL
showed	NULL
increased	NULL
amounts	NULL
of	NULL
NFxB	NULL
.	NULL

The	NULL
presence	NULL
of	NULL
p65	NULL
as	NULL
part	NULL
of	NULL
the	NULL
complex	NULL
was	NULL
confirmed	NULL
by	NULL
482	NULL
\	NULL
Optical	NULL
density	NULL
(	NULL
relative	NULL
contour	NULL
OD	NULL
x	NULL
square	NULL
)	NULL
bJ	NULL
to	NULL
B	NULL
in	NULL
&	NULL
~	NULL
Co	NULL
-s	NULL
I	NULL
I	NULL
Before	NULL
After	NULL
steroids	NULL
steroids	NULL
o	NULL
Figure	NULL
5	NULL
-	NULL
Nuclear	NULL
NFKB	NULL
p65	NULL
from	NULL
colonoscopic	NULL
biopsy	NULL
specimens	NULL
from	NULL
patients	NULL
with	NULL
inflammatory	NULL
bowel	NULL
disease	NULL
is	NULL
decreased	NULL
by	NULL
steroid	NULL
treatment	NULL
.	NULL

Sigmoid	NULL
biopsy	NULL
specimens	NULL
were	NULL
obtained	NULL
from	NULL
patients	NULL
with	NULL
moderately	NULL
to	NULL
highly	NULL
active	NULL
ileocolonic	NULL
Crohn	NULL
's	NULL
disease	NULL
and	NULL
involvement	NULL
of	NULL
the	NULL
sigmoid	NULL
(	NULL
CDAI	NULL
250-450	NULL
)	NULL
.	NULL

Nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
and	NULL
concentrations	NULL
of	NULL
NFB	NULL
p65	NULL
were	NULL
assessed	NULL
by	NULL
western	NULL
blot	NULL
.	NULL

Seven	NULL
days	NULL
of	NULL
treatment	NULL
with	NULL
steroids	NULL
(	NULL
60	NULL
mg	NULL
prednisolone/day	NULL
per	NULL
os	NULL
in	NULL
addition	NULL
to	NULL
5	NULL
mg	NULL
betamethasone	NULL
twice	NULL
daily	NULL
as	NULL
an	NULL
enema	NULL
)	NULL
induced	NULL
a	NULL
significant	NULL
reduction	NULL
(	NULL
p	NULL
=	NULL
0.0156	NULL
)	NULL
in	NULL
nuclear	NULL
NFKB	NULL
p65	NULL
concentration	NULL
.	NULL

IxBa	NULL
levels	NULL
remained	NULL
unchanged	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

supershift	NULL
assays	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
parallel	NULL
assessment	NULL
of	NULL
nuclear	NULL
p65	NULL
levels	NULL
by	NULL
western	NULL
blot	NULL
again	NULL
showed	NULL
higher	NULL
levels	NULL
of	NULL
NFxB	NULL
p65	NULL
in	NULL
nuclear	NULL
extracts	NULL
from	NULL
Crohn	NULL
's	NULL
disease	NULL
LPMNCs	NULL
than	NULL
in	NULL
ulcerative	NULL
colitis	NULL
or	NULL
controls	NULL
(	NULL
fig	NULL
3B	NULL
)	NULL
.	NULL

INHIBITION	NULL
OF	NULL
NFKB	NULL
TRANSLOCATION	NULL
DOWN-REGULATES	NULL
PRO-INFLAMMATORY	NULL
CYTOKINE	NULL
SECRETION	NULL
BY	NULL
IBD	NULL
LPMNCS	NULL
The	NULL
serine	NULL
protease	NULL
inhibitor	NULL
TPCK	NULL
inhibits	NULL
activation	NULL
of	NULL
NFxB	NULL
by	NULL
preventing	NULL
nuclear	NULL
translocation	NULL
of	NULL
both	NULL
p65	NULL
and	NULL
p50	NULL
through	NULL
stabilisation	NULL
of	NULL
IxBa	NULL
.	NULL
``	NULL

As	NULL
table	NULL
2	NULL
shows	NULL
,	NULL
TPCK	NULL
down-regulates	NULL
pro-inflammatory	NULL
cytokine	NULL
secretion	NULL
by	NULL
IBD	NULL
LPMNCs	NULL
in	NULL
a	NULL
similar	NULL
fashion	NULL
to	NULL
dexamethasone	NULL
.	NULL

As	NULL
expected	NULL
,	NULL
dexamethasone	NULL
as	NULL
well	NULL
as	NULL
TPCK	NULL
greatly	NULL
reduced	NULL
LPS	NULL
stimulated	NULL
nuclear	NULL
levels	NULL
of	NULL
oligonucleotide	NULL
Steroids	NULL
TNF-	NULL
«	NULL
,	NULL
LPS	NULL
NFxB	NULL
NFB	NULL
dimer	NULL
dimer	NULL
Inhibition	NULL
/Ac1ivation	NULL
NFB	NULL
NFB	NULL
COQ	NULL
``	NULL
-	NULL
o	NULL
``	NULL
IxBa	NULL
IxBa	NULL
NFB	NULL
dimer	NULL
EEK	NULL
Transcriptional	NULL
regulation	NULL
of	NULL
inflammation	NULL
genes	NULL
Stabilisation	NULL
of	NULL
-	NULL
Site	NULL
specific	NULL
phosphorylation	NULL
IcBo	NULL
and	NULL
degradation	NULL
Figure	NULL
6	NULL
-	NULL
Schematic	NULL
repr	NULL
ion	NULL
of	NULL
NFKB	NULL
activation	NULL
and	NULL
inhibition	NULL
by	NULL
steroids	NULL
.	NULL

Activating	NULL
stimuli	NULL
including	NULL
tumour	NULL
necrosis	NULL
factor	NULL
a	NULL
(	NULL
TNF-a	NULL
)	NULL
and	NULL
lipopolysaccharide	NULL
(	NULL
LPS	NULL
)	NULL
promote	NULL
degradation	NULL
of	NULL
IxBa	NULL
and	NULL
the	NULL
subsequent	NULL
release	NULL
of	NULL
NFB	NULL
p65	NULL
into	NULL
the	NULL
cytosolic	NULL
compartment	NULL
.	NULL

NFkB	NULL
p65	NULL
translocates	NULL
into	NULL
the	NULL
nucleus	NULL
and	NULL
forms	NULL
dimers	NULL
as	NULL
part	NULL
of	NULL
the	NULL
activation	NULL
process	NULL
.	NULL

Functionally	NULL
active	NULL
NFKB	NULL
can	NULL
then	NULL
bind	NULL
to	NULL
specific	NULL
sites	NULL
in	NULL
inflammation	NULL
gene	NULL
promoter	NULL
regions	NULL
and	NULL
initiate	NULL
transcription	NULL
.	NULL

Steroids	NULL
appear	NULL
to	NULL
stabilise	NULL
IxBa	NULL
against	NULL
activation	NULL
induced	NULL
degradation	NULL
and	NULL
thereby	NULL
reduce	NULL
the	NULL
amount	NULL
of	NULL
functionally	NULL
active	NULL
NFB	NULL
available	NULL
in	NULL
the	NULL
nucleus	NULL
.	NULL

Schreiber	NULL
,	NULL
Nikolaus	NULL
,	NULL
Hampe	NULL
binding	NULL
of	NULL
activated	NULL
NFxB	NULL
(	NULL
fig	NULL
4A	NULL
)	NULL
.	NULL

Dexamethasone	NULL
as	NULL
well	NULL
as	NULL
TPCK	NULL
stabilised	NULL
IxBa	NULL
against	NULL
LPS	NULL
induced	NULL
proteolysis	NULL
analogously	NULL
to	NULL
the	NULL
effect	NULL
previously	NULL
described	NULL
in	NULL
peripheral	NULL
blood	NULL
mononuclear	NULL
cells	NULL
(	NULL
fig	NULL
4B	NULL
)	NULL
.	NULL

STEROID	NULL
TREATMENT	NULL
REDUCES	NULL
ACTIVATION	NULL
OF	NULL
NFKB	NULL
Nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
from	NULL
sigmoid	NULL
biopsy	NULL
samples	NULL
from	NULL
seven	NULL
patients	NULL
with	NULL
highly	NULL
active	NULL
Crohn	NULL
's	NULL
ileocolitis	NULL
and	NULL
additional	NULL
inflammation	NULL
in	NULL
the	NULL
sigma	NULL
(	NULL
CDAI	NULL
250-450	NULL
)	NULL
,	NULL
before	NULL
they	NULL
received	NULL
steroid	NULL
treatment	NULL
.	NULL

Patients	NULL
were	NULL
examined	NULL
again	NULL
after	NULL
seven	NULL
days	NULL
of	NULL
treatment	NULL
with	NULL
high	NULL
dose	NULL
systemic	NULL
(	NULL
60	NULL
mg	NULL
prednisolone/day	NULL
)	NULL
and	NULL
topical	NULL
(	NULL
5	NULL
mg	NULL
betamethasone	NULL
in	NULL
100	NULL
ml	NULL
,	NULL
twice	NULL
daily	NULL
)	NULL
steroids	NULL
.	NULL

Nuclear	NULL
levels	NULL
of	NULL
NFxB	NULL
were	NULL
decreased	NULL
in	NULL
all	NULL
patients	NULL
by	NULL
steroid	NULL
treatment	NULL
(	NULL
fig	NULL
5	NULL
;	NULL
p	NULL
=	NULL
0.0156	NULL
)	NULL
,	NULL
whereas	NULL
IxBa	NULL
concentrations	NULL
remained	NULL
unchanged	NULL
or	NULL
were	NULL
also	NULL
decreased	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Discussion	NULL
Both	NULL
IL-18	NULL
and	NULL
TNF-a	NULL
have	NULL
been	NULL
suggested	NULL
to	NULL
be	NULL
important	NULL
mediators	NULL
involved	NULL
in	NULL
the	NULL
initiation	NULL
and	NULL
perpetuation	NULL
of	NULL
intestinal	NULL
inflammation	NULL
in	NULL
IBD	NULL
.	NULL

Increased	NULL
secretion	NULL
by	NULL
isolated	NULL
IBD	NULL
LPMNCs	NULL
as	NULL
well	NULL
as	NULL
whole	NULL
biopsy	NULL
samples	NULL
has	NULL
been	NULL
shown	NULL
in	NULL
comparison	NULL
with	NULL
normal	NULL
control	NULL
cells	NULL
.	NULL

Activation	NULL
of	NULL
NFxB	NULL
may	NULL
be	NULL
a	NULL
pivotal	NULL
event	NULL
in	NULL
pro-inflammatory	NULL
-	NULL
signal	NULL
Transcription	NULL
factor	NULL
members	NULL
of	NULL
the	NULL
Rel-NFxB	NULL
family	NULL
,	NULL
which	NULL
in	NULL
resting	NULL
cells	NULL
are	NULL
bound	NULL
to	NULL
cytoplasmic	NULL
inhibitory	NULL
factors	NULL
(	NULL
for	NULL
example	NULL
IxB	NULL
,	NULL
NFxB	NULL
p105	NULL
)	NULL
,	NULL
are	NULL
released	NULL
on	NULL
activation	NULL
induced	NULL
degradation	NULL
of	NULL
their	NULL
cytoplasmic	NULL
inhibitors	NULL
by	NULL
the	NULL
proteasome/ubiquitin	NULL
complex	NULL
.	NULL
``	NULL

``	NULL
~	NULL
``	NULL
**	NULL
NFxB	NULL
p65	NULL
hetero-	NULL
or	NULL
homodimers	NULL
migrate	NULL
to	NULL
the	NULL
nucleus	NULL
and	NULL
regulate	NULL
transcriptional	NULL
activity	NULL
by	NULL
binding	NULL
to	NULL
specific	NULL
DNA	NULL
sequences	NULL
in	NULL
promoter/enhancer	NULL
regions	NULL
of	NULL
inflammation	NULL
genes	NULL
.	NULL
``	NULL

°	NULL
We	NULL
therefore	NULL
investigated	NULL
both	NULL
the	NULL
level	NULL
of	NULL
nuclear	NULL
NFB	NULL
p65	NULL
protein	NULL
and	NULL
oligonucleotide	NULL
binding	NULL
of	NULL
activated	NULL
nuclear	NULL
NFxB	NULL
.	NULL

Intestinal	NULL
biopsy	NULL
specimens	NULL
were	NULL
investigated	NULL
because	NULL
they	NULL
reflect	NULL
the	NULL
in	NULL
vivo	NULL
state	NULL
of	NULL
NFxB	NULL
activation	NULL
without	NULL
any	NULL
potential	NULL
alterations	NULL
that	NULL
may	NULL
be	NULL
caused	NULL
by	NULL
in	NULL
vitro	NULL
isolation	NULL
procedures	NULL
.	NULL

We	NULL
found	NULL
increased	NULL
amounts	NULL
of	NULL
NFxB	NULL
p65	NULL
protein	NULL
in	NULL
nuclear	NULL
extracts	NULL
of	NULL
mucosal	NULL
biopsy	NULL
samples	NULL
of	NULL
patients	NULL
with	NULL
Crohn	NULL
's	NULL
disease	NULL
and	NULL
ulcerative	NULL
colitis	NULL
in	NULL
comparison	NULL
with	NULL
both	NULL
disease	NULL
specificity	NULL
controls	NULL
and	NULL
normal	NULL
controls	NULL
.	NULL

The	NULL
highest	NULL
levels	NULL
were	NULL
seen	NULL
consistently	NULL
in	NULL
lamina	NULL
propria	NULL
biopsy	NULL
samples	NULL
from	NULL
patients	NULL
with	NULL
Crohn	NULL
's	NULL
disease	NULL
.	NULL

Potential	NULL
candidates	NULL
responsible	NULL
for	NULL
the	NULL
activation	NULL
of	NULL
the	NULL
NFB	NULL
system	NULL
in	NULL
Crohn	NULL
's	NULL
disease	NULL
may	NULL
include	NULL
TNF-a	NULL
.	NULL

Recent	NULL
immunological	NULL
as	NULL
well	NULL
as	NULL
therapeutic	NULL
studies	NULL
suggest	NULL
that	NULL
TNF-a	NULL
plays	NULL
a	NULL
major	NULL
role	NULL
in	NULL
the	NULL
pathophysiology	NULL
of	NULL
intestinal	NULL
inflammation	NULL
in	NULL
Crohn	NULL
's	NULL
disease	NULL
``	NULL
but	NULL
it	NULL
may	NULL
be	NULL
less	NULL
important	NULL
in	NULL
chronic	NULL
ulcerative	NULL
colitis	NULL
.	NULL
``	NULL

The	NULL
increased	NULL
nuclear	NULL
concentrations	NULL
of	NULL
NFxB	NULL
p65	NULL
detected	NULL
in	NULL
IBD	NULL
mucosal	NULL
biopsy	NULL
samples	NULL
may	NULL
partially	NULL
be	NULL
a	NULL
product	NULL
of	NULL
TNF	NULL
stimulation	NULL
by	NULL
non-immune	NULL
cells-for	NULL
example	NULL
,	NULL
epithelial	NULL
cells	NULL
.	NULL

TNF	NULL
induced	NULL
involvement	NULL
of	NULL
NFxB	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
inflamma-	NULL
NFB	NULL
in	NULL
inflammatory	NULL
bowel	NULL
disease	NULL
tion	NULL
genes	NULL
in	NULL
these	NULL
cells	NULL
may	NULL
be	NULL
an	NULL
important	NULL
regulatory	NULL
mechanism	NULL
in	NULL
the	NULL
inflammatory	NULL
process	NULL
.	NULL

Several	NULL
other	NULL
cell	NULL
types	NULL
should	NULL
also	NULL
be	NULL
discussed	NULL
as	NULL
potential	NULL
contributors	NULL
to	NULL
the	NULL
activation	NULL
of	NULL
the	NULL
NFxB	NULL
system	NULL
seen	NULL
in	NULL
intestinal	NULL
lamina	NULL
propria	NULL
in	NULL
IBD	NULL
.	NULL

Protein	NULL
concentrations	NULL
(	NULL
as	NULL
assessed	NULL
by	NULL
western	NULL
blot	NULL
)	NULL
of	NULL
NFxB	NULL
p65	NULL
and	NULL
IxBa	NULL
were	NULL
not	NULL
different	NULL
in	NULL
intestinal	NULL
mucosa	NULL
from	NULL
patients	NULL
with	NULL
IBD	NULL
,	NULL
disease	NULL
specificity	NULL
controls	NULL
and	NULL
normal	NULL
controls	NULL
if	NULL
total	NULL
tissue	NULL
extracts	NULL
were	NULL
not	NULL
separated	NULL
into	NULL
cytoplasmic	NULL
and	NULL
nuclear	NULL
extracts	NULL
.	NULL

This	NULL
finding	NULL
is	NULL
expected	NULL
because	NULL
activation	NULL
of	NULL
NFxB	NULL
results	NULL
in	NULL
a	NULL
shift	NULL
from	NULL
the	NULL
cytoplasm	NULL
to	NULL
the	NULL
nucleus	NULL
.	NULL

Moreover	NULL
,	NULL
IxB	NULL
concentrations	NULL
,	NULL
which	NULL
are	NULL
decreased	NULL
by	NULL
degradation	NULL
in	NULL
response	NULL
to	NULL
a	NULL
stimulus	NULL
,	NULL
rapidly	NULL
returned	NULL
to	NULL
their	NULL
original	NULL
levels	NULL
in	NULL
vitro	NULL
within	NULL
less	NULL
than	NULL
90	NULL
minutes	NULL
.	NULL
``	NULL

''	NULL
Translocation	NULL
into	NULL
the	NULL
nucleus	NULL
and	NULL
binding	NULL
to	NULL
specific	NULL
DNA	NULL
sequences	NULL
are	NULL
important	NULL
events	NULL
which	NULL
are	NULL
prerequisites	NULL
for	NULL
transcriptional	NULL
control	NULL
by	NULL
NFxB	NULL
.	NULL

Enhanced	NULL
detection	NULL
of	NULL
NFxB	NULL
p65	NULL
protein	NULL
should	NULL
therefore	NULL
be	NULL
accompanied	NULL
by	NULL
increased	NULL
availability	NULL
of	NULL
oligonucleotide	NULL
binding	NULL
of	NULL
NFxB	NULL
.	NULL

Increased	NULL
nuclear	NULL
levels	NULL
of	NULL
consensus	NULL
oligonucleotide	NULL
binding	NULL
of	NULL
activated	NULL
NFxB	NULL
were	NULL
detected	NULL
in	NULL
both	NULL
Crohn	NULL
's	NULL
disease	NULL
and	NULL
ulcerative	NULL
colitis	NULL
biopsy	NULL
samples	NULL
as	NULL
well	NULL
as	NULL
LPMNCs	NULL
in	NULL
comparison	NULL
with	NULL
normal	NULL
controls	NULL
.	NULL

Crohn	NULL
's	NULL
disease	NULL
LPMNCs	NULL
again	NULL
appeared	NULL
to	NULL
contain	NULL
more	NULL
NFxB	NULL
p65	NULL
protein	NULL
in	NULL
nuclear	NULL
extracts	NULL
than	NULL
LPMNCs	NULL
from	NULL
patients	NULL
with	NULL
ulcerative	NULL
colitis	NULL
.	NULL

The	NULL
heightened	NULL
activation	NULL
of	NULL
NFxB	NULL
could	NULL
be	NULL
a	NULL
major	NULL
regulator	NULL
of	NULL
pro-inflammatory	NULL
cytokine	NULL
secretion	NULL
in	NULL
IBD	NULL
.	NULL

However	NULL
,	NULL
a	NULL
host	NULL
of	NULL
other	NULL
activating	NULL
stimuli	NULL
,	NULL
including	NULL
TNF	NULL
and	NULL
LPS	NULL
,	NULL
may	NULL
also	NULL
induce	NULL
the	NULL
activation	NULL
of	NULL
NFxB	NULL
as	NULL
a	NULL
secondary	NULL
event	NULL
.	NULL

In	NULL
order	NULL
to	NULL
dissect	NULL
the	NULL
regulatory	NULL
role	NULL
of	NULL
NFxB	NULL
in	NULL
IBD	NULL
,	NULL
we	NULL
tried	NULL
to	NULL
block	NULL
the	NULL
release	NULL
of	NULL
cytosolic	NULL
NFxB	NULL
proteins	NULL
into	NULL
the	NULL
nuclear	NULL
compartment	NULL
using	NULL
the	NULL
serine	NULL
protease	NULL
inhibitor	NULL
TPCK	NULL
.	NULL
``	NULL

TPCK	NULL
strongly	NULL
down-regulated	NULL
the	NULL
increased	NULL
secretion	NULL
of	NULL
the	NULL
pro-inflammatory	NULL
cytokines	NULL
TNF-a	NULL
and	NULL
IL-18	NULL
in	NULL
LPMNCs	NULL
from	NULL
patients	NULL
with	NULL
IBD	NULL
.	NULL

These	NULL
experiments	NULL
indicate	NULL
a	NULL
regulatory	NULL
role	NULL
for	NULL
activated	NULL
NFB	NULL
in	NULL
the	NULL
inflammatory	NULL
cytokine	NULL
response	NULL
in	NULL
IBD	NULL
.	NULL

Moreover	NULL
,	NULL
it	NULL
appears	NULL
that	NULL
NFxB	NULL
p65	NULL
(	NULL
RelA	NULL
)	NULL
,	NULL
which	NULL
has	NULL
been	NULL
suggested	NULL
to	NULL
have	NULL
a	NULL
greater	NULL
pro-inflammatory	NULL
role	NULL
in	NULL
the	NULL
induction	NULL
of	NULL
inflammation	NULL
gene	NULL
expression	NULL
than	NULL
p50	NULL
,	NULL
``	NULL
is	NULL
an	NULL
important	NULL
factor	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
intestinal	NULL
inflammation	NULL
in	NULL
IBD	NULL
.	NULL

Our	NULL
results	NULL
which	NULL
demonstrate	NULL
increased	NULL
nuclear	NULL
levels	NULL
of	NULL
NFB	NULL
p65	NULL
as	NULL
well	NULL
as	NULL
activated	NULL
oligonucleotide	NULL
binding	NULL
of	NULL
NFxB	NULL
in	NULL
IBD	NULL
support	NULL
the	NULL
concept	NULL
of	NULL
a	NULL
perpetuating	NULL
stimulation	NULL
of	NULL
the	NULL
NFxB	NULL
system	NULL
,	NULL
which	NULL
is	NULL
characterised	NULL
by	NULL
rapid	NULL
activation	NULL
and	NULL
de-activation	NULL
kinetics	NULL
.	NULL
``	NULL

''	NULL
In	NULL
vitro	NULL
exposure	NULL
to	NULL
steroids	NULL
rapidly	NULL
inhibits	NULL
NFxB	NULL
activation	NULL
.	NULL

Previous	NULL
reports	NULL
have	NULL
shown	NULL
that	NULL
glucocorticoids	NULL
use	NULL
stabilisation	NULL
of	NULL
IxBa	NULL
as	NULL
part	NULL
of	NULL
their	NULL
anti-inflammatory	NULL
mechanism	NULL
of	NULL
action	NULL
.	NULL
``	NULL

*	NULL
Our	NULL
study	NULL
confirms	NULL
that	NULL
steroids	NULL
cause	NULL
in	NULL
vitro	NULL
reduction	NULL
of	NULL
activated	NULL
NFxB	NULL
in	NULL
IBD	NULL
LPM-NCs	NULL
.	NULL

Moreover	NULL
,	NULL
in	NULL
vivo	NULL
treatment	NULL
with	NULL
high	NULL
dose	NULL
steroids	NULL
leads	NULL
to	NULL
inhibition	NULL
of	NULL
NFxB	NULL
p65	NULL
activation	NULL
in	NULL
Crohn	NULL
's	NULL
disease	NULL
,	NULL
which	NULL
paralleled	NULL
clinical	NULL
improvement	NULL
of	NULL
patients	NULL
.	NULL

However	NULL
,	NULL
this	NULL
483	NULL
inhibition	NULL
of	NULL
NFxB	NULL
activation	NULL
was	NULL
not	NULL
accompanied	NULL
by	NULL
in	NULL
vivo	NULL
enhancement	NULL
of	NULL
IxBa	NULL
,	NULL
as	NULL
would	NULL
have	NULL
been	NULL
expected	NULL
from	NULL
in	NULL
vitro	NULL
systems	NULL
.	NULL
``	NULL

``	NULL
°	NULL
Studies	NULL
currently	NULL
being	NULL
performed	NULL
therefore	NULL
examine	NULL
the	NULL
role	NULL
of	NULL
the	NULL
IxB/NFxB	NULL
system	NULL
during	NULL
clinical	NULL
relapse	NULL
of	NULL
disease	NULL
from	NULL
remission	NULL
and	NULL
in	NULL
experimental	NULL
treatment	NULL
situations	NULL
in	NULL
IBD	NULL
(	NULL
glucocorticoids	NULL
,	NULL
IL-10	NULL
,	NULL
anti-TNF	NULL
antibodies	NULL
)	NULL
.	NULL

Activation	NULL
of	NULL
NFxB	NULL
may	NULL
play	NULL
a	NULL
central	NULL
role	NULL
in	NULL
the	NULL
initiation	NULL
of	NULL
the	NULL
relapsing	NULL
inflammatory	NULL
process	NULL
and	NULL
moreover	NULL
may	NULL
be	NULL
targeted	NULL
by	NULL
the	NULL
therapeutic	NULL
mechanism	NULL
of	NULL
various	NULL
-	NULL
anti-inflammatory	NULL
-	NULL
drugs	NULL
-	NULL
including	NULL
corticosteroids	NULL
``	NULL
*	NULL
and	NULL
aminosalicylates	NULL
(	NULL
fig	NULL
6	NULL
)	NULL
.	NULL
``	NULL

Activation	NULL
of	NULL
NFB	NULL
may	NULL
be	NULL
a	NULL
pivotal	NULL
element	NULL
in	NULL
the	NULL
pathophysiology	NULL
of	NULL
chronic	NULL
intestinal	NULL
inflammation	NULL
,	NULL
but	NULL
is	NULL
unlikely	NULL
to	NULL
be	NULL
the	NULL
primary	NULL
cause	NULL
of	NULL
IBD	NULL
.	NULL

Parts	NULL
of	NULL
this	NULL
work	NULL
have	NULL
been	NULL
presented	NULL
at	NULL
the	NULL
5th	NULL
European	NULL
Gastroenterology	NULL
Week	NULL
in	NULL
Paris	NULL
,	NULL
France	NULL
(	NULL
1996	NULL
)	NULL
.	NULL

This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
a	NULL
t	NULL
from	NULL
the	NULL
Deutsche	NULL
Forschungsgemein-schaft	NULL
(	NULL
SCH	NULL
512/1-2	NULL
to	NULL
S	NULL
S	NULL
)	NULL
,	NULL
by	NULL
an	NULL
award	NULL
from	NULL
the	NULL
German	NULL
Crohn	NULL
's	NULL
and	NULL
Colitis	NULL
Foundation	NULL
(	NULL
DCCV	NULL
,	NULL
to	NULL
S	NULL
N	NULL
)	NULL
,	NULL
by	NULL
a	NULL
student	NULL
research	NULL
prize	NULL
from	NULL
the	NULL
Ministry	NULL
of	NULL
Science	NULL
of	NULL
Saxony	NULL
,	NULL
Germany	NULL
(	NULL
to	NULL
J	NULL
H	NULL
)	NULL
and	NULL
by	NULL
development	NULL
grants	NULL
from	NULL
the	NULL
Genzyme	NULL
GmbH	NULL
and	NULL
Syngen	NULL
Pharma	NULL
GmbH	NULL
.	NULL

The	NULL
authors	NULL
gratefully	NULL
appreciate	NULL
critical	NULL
advice	NULL
from	NULL
H	NULL
Lochs	NULL
(	NULL
Berlin	NULL
}	NULL
,	NULL
A	NULL
Raedler	NULL
(	NULL
Hamburg	NULL
)	NULL
,	NULL
and	NULL
U	NULL
Schindler	NULL
(	NULL
South	NULL
San	NULL
Francisco	NULL
)	NULL
as	NULL
well	NULL
as	NULL
excellent	NULL
technical	NULL
help	NULL
from	NULL
A	NULL
M	NULL
Wenner	NULL
and	NULL
S	NULL
Eidner	NULL
The	NULL
contribution	NULL
of	NULL
the	NULL
endoscopy	NULL
staff	NULL
as	NULL
well	NULL
as	NULL
S	NULL
Wedel	NULL
in	NULL
obtaining	NULL
biopsy	NULL
specimens	NULL
and	NULL
recruiting	NULL
patients	NULL
is	NULL
gratefully	NULL
acknowledged	NULL
.	NULL

The	NULL
authors	NULL
are	NULL
indebted	NULL
to	NULL
the	NULL
healthy	NULL
volunteers	NULL
who	NULL
served	NULL
as	NULL
normal	NULL
controls	NULL
.	NULL

1	NULL
Mahida	NULL
YR	NULL
,	NULL
Wu	NULL
K	NULL
,	NULL
Jewell	NULL
DP	NULL
.	NULL

Enhanced	NULL
production	NULL
of	NULL
interleukin	NULL
1-8	NULL
by	NULL
mononuclear	NULL
cells	NULL
isolated	NULL
from	NULL
mucosa	NULL
with	NULL
active	NULL
ulcerative	NULL
colitis	NULL
or	NULL
Crohn	NULL
's	NULL
discase	NULL
.	NULL

Gut	NULL
1989	NULL
;	NULL
30:835-8	NULL
.	NULL

Ligumsky	NULL
M	NULL
,	NULL
Simon	NULL
PL	NULL
,	NULL
Karmeli	NULL
F	NULL
,	NULL
Rachmilewitz	NULL
D.	NULL
Role	NULL
of	NULL
interleukin	NULL
1	NULL
in	NULL
inflammatory	NULL
bowel	NULL
disease	NULL
:	NULL
enhanced	NULL
production	NULL
during	NULL
active	NULL
discase	NULL
.	NULL

Gut	NULL
1990	NULL
;	NULL
31:686-9	NULL
.	NULL

3	NULL
MacDonald	NULL
TT	NULL
,	NULL
Hutchings	NULL
P	NULL
,	NULL
Choy	NULL
MY	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Tumour	NULL
necrosis	NULL
factor-alpha	NULL
and	NULL
interferon-gamma	NULL
production	NULL
measured	NULL
at	NULL
the	NULL
single	NULL
cell	NULL
level	NULL
in	NULL
normal	NULL
and	NULL
inflamed	NULL
human	NULL
intestine	NULL
.	NULL

Clin	NULL
Exp	NULL
Immunol	NULL
1990	NULL
;	NULL
81:301-5	NULL
.	NULL

Stevens	NULL
C	NULL
,	NULL
Walz	NULL
G	NULL
,	NULL
Singaram	NULL
C	NULL
,	NULL
ef	NULL
al	NULL
.	NULL

Tumor	NULL
necrosis	NULL
factor-a	NULL
,	NULL
interlcukin-18	NULL
and	NULL
interleukin	NULL
6	NULL
expression	NULL
in	NULL
inflammatory	NULL
bowel	NULL
disease	NULL
.	NULL

Dig	NULL
Dis	NULL
Sci	NULL
1992	NULL
;	NULL
37:818-26	NULL
.	NULL

Isaacs	NULL
KL	NULL
,	NULL
Sartor	NULL
RB	NULL
,	NULL
Haskill	NULL
S.	NULL
Cytokine	NULL
messenger	NULL
RNA	NULL
profiles	NULL
in	NULL
inflammatory	NULL
bowel	NULL
disease	NULL
mucosa	NULL
detected	NULL
by	NULL
polymerase	NULL
chain	NULL
reaction	NULL
amplification	NULL
.	NULL

Gastroenterology	NULL
1992	NULL
;	NULL
103:1587-95	NULL
.	NULL

Reinecker	NULL
H-C	NULL
,	NULL
Steffen	NULL
M	NULL
,	NULL
Witthocft	NULL
T	NULL
,	NULL
e	NULL
al	NULL
.	NULL

Enhanced	NULL
secretion	NULL
of	NULL
tumor	NULL
necrosis	NULL
factor-alpha	NULL
,	NULL
IL-6	NULL
,	NULL
and	NULL
IL-1	NULL
beta	NULL
by	NULL
isolated	NULL
lamina	NULL
propria	NULL
mononuclear	NULL
cells	NULL
from	NULL
patients	NULL
with	NULL
ulcerative	NULL
colitis	NULL
and	NULL
Crohn	NULL
's	NULL
discase	NULL
.	NULL

Cin	NULL
Exp	NULL
Immunol	NULL
1993	NULL
;	NULL
94:174-81	NULL
.	NULL

Nicholls	NULL
S	NULL
,	NULL
Stephens	NULL
S	NULL
,	NULL
Bracgger	NULL
CP	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Cytokines	NULL
in	NULL
stools	NULL
of	NULL
children	NULL
with	NULL
inflammatory	NULL
bowel	NULL
disease	NULL
or	NULL
infective	NULL
diarthca	NULL
.	NULL

J	NULL
Clin	NULL
Pathol	NULL
1992	NULL
;	NULL
46:757-60	NULL
.	NULL

Lenardo	NULL
MJ	NULL
,	NULL
Baltimore	NULL
D.	NULL
NF-kappa	NULL
B	NULL
:	NULL
a	NULL
pleiotropic	NULL
mediator	NULL
of	NULL
inducible	NULL
and	NULL
tissue-specific	NULL
gene	NULL
control	NULL
.	NULL

CelZ	NULL
1989	NULL
;	NULL
58:227-9	NULL
.	NULL

Baldwin	NULL
AS	NULL
.	NULL

The	NULL
NF-KB	NULL
and	NULL
I-KB	NULL
proteins	NULL
:	NULL
new	NULL
discoveries	NULL
and	NULL
insights	NULL
.	NULL

Annu	NULL
Rev	NULL
Immunol	NULL
1996	NULL
;	NULL
14:649-81	NULL
.	NULL

10	NULL
Hassanain	NULL
HH	NULL
,	NULL
Dai	NULL
W	NULL
,	NULL
Gupta	NULL
SL	NULL
.	NULL

Enhanced	NULL
gel	NULL
mobility	NULL
shift	NULL
assay	NULL
for	NULL
DNA-binding	NULL
factors	NULL
.	NULL

Anal	NULL
Biochem	NULL
1993	NULL
;	NULL
213:162-7	NULL
.	NULL

Brown	NULL
K	NULL
,	NULL
Gerstberger	NULL
S	NULL
,	NULL
Carlson	NULL
L	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Control	NULL
of	NULL
IxB-u	NULL
proteolysis	NULL
by	NULL
site-specific	NULL
signal	NULL
induced	NULL
phosphorylation	NULL
.	NULL

Science	NULL
1995	NULL
;	NULL
267	NULL
:	NULL
1485-7	NULL
.	NULL

12	NULL
Traenckner	NULL
EB	NULL
,	NULL
Wilk	NULL
S	NULL
,	NULL
Baeuerle	NULL
PA.	NULL
A	NULL
proteasome	NULL
inhibitor	NULL
prevents	NULL
activation	NULL
of	NULL
NF-kappa	NULL
B	NULL
and	NULL
stabilizes	NULL
a	NULL
newly	NULL
phosphorylated	NULL
form	NULL
of	NULL
I-kappa	NULL
B-alpha	NULL
that	NULL
is	NULL
still	NULL
bound	NULL
to	NULL
NF-kappa	NULL
B.	NULL
EMBO	NULL
J	NULL
1994	NULL
;	NULL
13:5433-41	NULL
.	NULL

13	NULL
Scherer	NULL
DC	NULL
,	NULL
Brockman	NULL
JA	NULL
,	NULL
Chen	NULL
Z	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Signal-induced	NULL
degradation	NULL
of	NULL
I	NULL
kappa	NULL
B	NULL
alpha	NULL
requires	NULL
site-specific	NULL
ubig-uitination	NULL
.	NULL

Proc	NULL
Nail	NULL
Acad	NULL
Sci	NULL
USA	NULL
1995	NULL
;	NULL
92:11259-63	NULL
.	NULL

14	NULL
Kim	NULL
H	NULL
,	NULL
Lee	NULL
HS	NULL
,	NULL
Chang	NULL
KT	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Chlormethyl	NULL
ketones	NULL
block	NULL
induction	NULL
of	NULL
nitric	NULL
oxide	NULL
synthase	NULL
in	NULL
murine	NULL
macropahges	NULL
by	NULL
preventing	NULL
activation	NULL
of	NULL
nuclear	NULL
factor-kappa	NULL
B.	NULL
J	NULL
Immunol	NULL
1995	NULL
;	NULL
154:4741-8	NULL
.	NULL

15	NULL
Shakhov	NULL
AN	NULL
,	NULL
Collart	NULL
MA	NULL
,	NULL
Vassali	NULL
P	NULL
,	NULL
er	NULL
al	NULL
.	NULL

Kappa	NULL
B-type	NULL
enhancers	NULL
are	NULL
involved	NULL
in	NULL
lipopolysaccharide-mediated	NULL
transcriptional	NULL
activation	NULL
of	NULL
the	NULL
tumor	NULL
necrosis	NULL
factor	NULL
a	NULL
gene	NULL
in	NULL
primary	NULL
macrophages	NULL
.	NULL

J	NULL
Exp	NULL
Med	NULL
1990	NULL
;	NULL
171:35-47	NULL
.	NULL

Kunsch	NULL
C	NULL
,	NULL
Rosen	NULL
CA	NULL
.	NULL

NF-kappa	NULL
B	NULL
subunit	NULL
specific	NULL
regulation	NULL
in	NULL
the	NULL
interleukin-8	NULL
promoter	NULL
.	NULL

Cell	NULL
Biol	NULL
1993	NULL
;	NULL
13	NULL
:	NULL
6137-46	NULL
.	NULL

17	NULL
Ledebur	NULL
HC	NULL
,	NULL
Parks	NULL
TP	NULL
.	NULL

Transcriptional	NULL
regulation	NULL
of	NULL
the	NULL
intercellular	NULL
adhesion	NULL
molecule-	NULL
gene	NULL
by	NULL
inflammatory	NULL
cytokines	NULL
in	NULL
human	NULL
endothelial	NULL
cells	NULL
.	NULL

Essential	NULL
roles	NULL
of	NULL
a	NULL
bo	NULL
im	NULL
un	NULL
&	NULL
~	NULL
co	NULL
©	NULL
1	NULL
1	NULL
&	NULL
484	NULL
18	NULL
19	NULL
20	NULL
21	NULL
22	NULL
23	NULL
2	NULL
ss	NULL
2	NULL
Ut	NULL
26	NULL
27	NULL
28	NULL
variant	NULL
NE-kappa	NULL
B	NULL
site	NULL
and	NULL
p65	NULL
homodimers	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
1995	NULL
;	NULL
270:933-43	NULL
.	NULL

Ziegler-Heitbrock	NULL
HW	NULL
,	NULL
Sternsdorf	NULL
T	NULL
,	NULL
Liese	NULL
J	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Pyrrolid-inc	NULL
dithiocarbamate	NULL
inhibits	NULL
NF-kappa	NULL
B	NULL
mobilization	NULL
and	NULL
TNF	NULL
production	NULL
in	NULL
human	NULL
monocytes	NULL
.	NULL

J	NULL
Immunol	NULL
1993	NULL
;	NULL
151:6986-93	NULL
.	NULL

Ziegler-Heitbrock	NULL
HW	NULL
,	NULL
Wedel	NULL
A	NULL
,	NULL
Schraut	NULL
W	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Tolerance	NULL
to	NULL
lipopolysaccharides	NULL
involves	NULL
mobilization	NULL
of	NULL
nuclear	NULL
factor	NULL
kappa	NULL
B	NULL
with	NULL
predominance	NULL
of	NULL
p50	NULL
homodimers	NULL
.	NULL

J	NULL
Bio/	NULL
Chem	NULL
19943269	NULL
:	NULL
17001-4	NULL
.	NULL

Neurath	NULL
MF	NULL
,	NULL
Petterson	NULL
S	NULL
,	NULL
Meyer	NULL
zum	NULL
Biischenfelde	NULL
KH	NULL
,	NULL
Strober	NULL
W.	NULL
Local	NULL
administration	NULL
of	NULL
antisense	NULL
phospho-rothioate	NULL
oligonucleotides	NULL
to	NULL
the	NULL
p65	NULL
subunit	NULL
of	NULL
NF-xB	NULL
abrogates	NULL
established	NULL
experimental	NULL
colitis	NULL
in	NULL
mice	NULL
.	NULL

Nature	NULL
Medicine	NULL
1996	NULL
;	NULL
2:998-1004	NULL
.	NULL

Schreiber	NULL
S	NULL
,	NULL
MacDermott	NULL
RP	NULL
,	NULL
Raedler	NULL
A	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Increased	NULL
activation	NULL
of	NULL
intestinal	NULL
lamina	NULL
propria	NULL
mononuclear	NULL
cells	NULL
in	NULL
inflammatory	NULL
bowel	NULL
discase	NULL
.	NULL

Gastroenterology	NULL
1991	NULL
;	NULL
101	NULL
:	NULL
1020-30	NULL
.	NULL

Schreiber	NULL
S	NULL
,	NULL
Heinig	NULL
T	NULL
,	NULL
Panzer	NULL
U	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Impaired	NULL
response	NULL
of	NULL
activated	NULL
mononuclear	NULL
phagocytes	NULL
to	NULL
interleukin	NULL
4	NULL
in	NULL
inflammatory	NULL
bowel	NULL
disease	NULL
.	NULL

Gastroenterology	NULL
1995	NULL
;	NULL
108:21-33	NULL
.	NULL

Hou	NULL
J	NULL
,	NULL
Schindler	NULL
U	NULL
,	NULL
Henzel	NULL
WJ	NULL
,	NULL
et	NULL
al	NULL
.	NULL

An	NULL
interleukin-4-induced	NULL
transcription	NULL
factor	NULL
:	NULL
IL-4	NULL
Stat	NULL
.	NULL

Science	NULL
19943265	NULL
:	NULL
1701-6	NULL
.	NULL

Osborn	NULL
L	NULL
,	NULL
Kunkel	NULL
S	NULL
,	NULL
Nabel	NULL
GJ	NULL
.	NULL

Tumor	NULL
necrosis	NULL
factor	NULL
and	NULL
interleukin	NULL
1	NULL
stimulate	NULL
the	NULL
human	NULL
immunodifficiency	NULL
virus	NULL
enhancer	NULL
by	NULL
activation	NULL
of	NULL
the	NULL
nuclear	NULL
factor	NULL
xB	NULL
.	NULL

Proc	NULL
Nail	NULL
Acad	NULL
Sci	NULL
USA	NULL
1989	NULL
;	NULL
86:2335-40	NULL
.	NULL

Scholtz	NULL
B	NULL
,	NULL
Lamb	NULL
K	NULL
,	NULL
Rosford	NULL
E	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Appearance	NULL
of	NULL
nuclear	NULL
protease	NULL
after	NULL
embryonal	NULL
carcicomal	NULL
cells	NULL
undergo	NULL
differen-tiation	NULL
.	NULL

Dev	NULL
Biol	NULL
1996	NULL
;	NULL
173:420-7	NULL
.	NULL

Dent	NULL
CL	NULL
,	NULL
Latchman	NULL
DS	NULL
.	NULL

The	NULL
overlapping	NULL
octamer/	NULL
TAATGARAT	NULL
motif	NULL
is	NULL
a	NULL
high-affinity	NULL
binding	NULL
site	NULL
for	NULL
the	NULL
cellular	NULL
transcription	NULL
factors	NULL
Oct-1	NULL
and	NULL
Oct-2	NULL
.	NULL

Biochem	NULL
J	NULL
1991	NULL
;	NULL
277:541-5	NULL
.	NULL

Henell	NULL
F	NULL
,	NULL
Glaumann	NULL
H.	NULL
Effect	NULL
of	NULL
leupeptin	NULL
on	NULL
the	NULL
autophagic	NULL
vacuolar	NULL
system	NULL
of	NULL
rat	NULL
hepatocytes	NULL
.	NULL

Correlation	NULL
between	NULL
ultrastructure	NULL
and	NULL
degradation	NULL
of	NULL
membrane	NULL
and	NULL
cytosolic	NULL
proteins	NULL
.	NULL

Lab	NULL
Invest	NULL
1984	NULL
;	NULL
51:46-56	NULL
.	NULL

Lowry	NULL
OH	NULL
,	NULL
Rosebrough	NULL
NJ	NULL
,	NULL
Farr	NULL
AL	NULL
,	NULL
Randall	NULL
RJ	NULL
.	NULL

Protein	NULL
measurements	NULL
with	NULL
the	NULL
folin	NULL
phenol	NULL
reagent	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
1951	NULL
;	NULL
193:265-75	NULL
.	NULL

29	NULL
30	NULL
3	NULL
32	NULL
33	NULL
34	NULL
35	NULL
36	NULL
37	NULL
38	NULL
39	NULL
40	NULL
41	NULL
Schreiber	NULL
,	NULL
Nikolaus	NULL
,	NULL
Hampe	NULL
Robhringer	NULL
R	NULL
,	NULL
Holden	NULL
DW	NULL
.	NULL

Protein	NULL
blotting	NULL
:	NULL
detection	NULL
of	NULL
proteins	NULL
with	NULL
colloidal	NULL
gold	NULL
,	NULL
and	NULL
of	NULL
glycoproteins	NULL
and	NULL
lectins	NULL
with	NULL
biotin-conjugated	NULL
and	NULL
enzyme	NULL
probes	NULL
.	NULL

Anal	NULL
Biochem	NULL
1985	NULL
;	NULL
144:118-27	NULL
.	NULL

Fried	NULL
MG	NULL
.	NULL

Measurement	NULL
of	NULL
protein-DNA	NULL
interaction	NULL
parameters	NULL
by	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
assay	NULL
.	NULL

Electro-phoresis	NULL
1989	NULL
;	NULL
10:366-76	NULL
.	NULL

Sambrook	NULL
J	NULL
,	NULL
Fritsch	NULL
EF	NULL
,	NULL
Maniatis	NULL
T.	NULL
Molecular	NULL
cloning	NULL
:	NULL
a	NULL
laboratory	NULL
manual	NULL
(	NULL
2nd	NULL
ed	NULL
)	NULL
.	NULL

Cold	NULL
Spring	NULL
Harbor	NULL
,	NULL
NY	NULL
:	NULL
Cold	NULL
Spring	NULL
Harbor	NULL
Laboratory	NULL
Press	NULL
,	NULL
1989	NULL
.	NULL

Lillicfors	NULL
HW	NULL
.	NULL

On	NULL
the	NULL
Kolmogorow-Smitnov	NULL
test	NULL
for	NULL
normality	NULL
with	NULL
mean	NULL
and	NULL
variance	NULL
unknown	NULL
.	NULL

Journal	NULL
of	NULL
the	NULL
American	NULL
Staustical	NULL
Association	NULL
1967	NULL
;	NULL
64:399-402	NULL
.	NULL

Sachs	NULL
L.	NULL
Angewandte	NULL
Staustik	NULL
(	NULL
7th	NULL
ed	NULL
)	NULL
.	NULL

Heidelberg	NULL
,	NULL
New	NULL
York	NULL
,	NULL
Tokyo	NULL
:	NULL
Springer	NULL
,	NULL
1992	NULL
.	NULL

Mann	NULL
HB	NULL
,	NULL
Whitney	NULL
DR.	NULL
On	NULL
a	NULL
test	NULL
of	NULL
whether	NULL
one	NULL
of	NULL
two	NULL
random	NULL
variables	NULL
is	NULL
stochastically	NULL
larger	NULL
than	NULL
the	NULL
other	NULL
.	NULL

Annals	NULL
of	NULL
Mathematical	NULL
Statistics	NULL
1947	NULL
;	NULL
18:50-60.	NULL
van	NULL
Dullemen	NULL
HM	NULL
,	NULL
van	NULL
Deventer	NULL
SJH	NULL
,	NULL
Hommes	NULL
DW	NULL
,	NULL
er	NULL
al	NULL
.	NULL

Treatment	NULL
of	NULL
Crohn	NULL
's	NULL
disease	NULL
with	NULL
anti-tumor	NULL
necrosis	NULL
factor	NULL
chimeric	NULL
antibody	NULL
(	NULL
cA2	NULL
)	NULL
.	NULL

Gastroenterology	NULL
1995	NULL
;	NULL
109	NULL
:	NULL
129-35	NULL
.	NULL

Bacrt	NULL
F	NULL
,	NULL
D'Hacens	NULL
G	NULL
,	NULL
Geboes	NULL
K	NULL
,	NULL
&	NULL
al	NULL
.	NULL

TNF-u	NULL
antibody	NULL
therapy	NULL
causes	NULL
a	NULL
fast	NULL
and	NULL
dramatic	NULL
decrease	NULL
of	NULL
histologic	NULL
colonic	NULL
inflammation	NULL
in	NULL
Crohn	NULL
's	NULL
disease	NULL
but	NULL
not	NULL
in	NULL
ulcerative	NULL
colitis	NULL
[	NULL
abstract	NULL
]	NULL
.	NULL

Gastroenterology	NULL
1996	NULL
;	NULL
110	NULL
:	NULL
A940	NULL
.	NULL

Scheinman	NULL
RI	NULL
,	NULL
Cogswell	NULL
PC	NULL
,	NULL
Lofquist	NULL
AK	NULL
,	NULL
Baldwin	NULL
Jr.	NULL
AS	NULL
.	NULL

Role	NULL
of	NULL
transcriptional	NULL
activation	NULL
by	NULL
IxB	NULL
in	NULL
mediation	NULL
of	NULL
immunosuppression	NULL
by	NULL
glucocorticoids	NULL
.	NULL

Science	NULL
1995	NULL
;	NULL
270	NULL
:	NULL
283-6	NULL
.	NULL

Auphan	NULL
N	NULL
,	NULL
DiDonato	NULL
JA	NULL
,	NULL
Rosette	NULL
C	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Immunosuppression	NULL
by	NULL
glucocorticoids	NULL
:	NULL
inhibition	NULL
of	NULL
NFkB	NULL
activity	NULL
through	NULL
induction	NULL
of	NULL
IkB	NULL
synthesis	NULL
.	NULL

Science	NULL
1995	NULL
;	NULL
270:286-90	NULL
.	NULL

Kopp	NULL
E	NULL
,	NULL
Ghosh	NULL
S.	NULL
Inhibition	NULL
of	NULL
NF-kappa	NULL
B	NULL
by	NULL
sodium	NULL
salicylate	NULL
and	NULL
aspirin	NULL
.	NULL

Science	NULL
1994	NULL
;	NULL
265:956-9	NULL
.	NULL

Best	NULL
WR	NULL
,	NULL
Becktel	NULL
JM	NULL
,	NULL
Singleton	NULL
JW	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Development	NULL
of	NULL
a	NULL
Crohn	NULL
's	NULL
discase	NULL
activity	NULL
index	NULL
:	NULL
National	NULL
Cooperative	NULL
Crohn	NULL
's	NULL
Disease	NULL
Study	NULL
.	NULL

Gastroenterology	NULL
1976	NULL
;	NULL
70:439-44	NULL
.	NULL

Rachmilewitz	NULL
D.	NULL
Coated	NULL
mesalazine	NULL
(	NULL
5-aminosalicylic	NULL
acid	NULL
)	NULL
versus	NULL
sulphasalazine	NULL
in	NULL
the	NULL
treatment	NULL
of	NULL
active	NULL
ulcerative	NULL
colitis	NULL
:	NULL
a	NULL
randomised	NULL
trial	NULL
.	NULL

BMJ	NULL
1989	NULL
;	NULL
298:82-6	NULL
.	NULL

